BIOMARKERS & PRECISION MEDICINE 2025

30 September - 01 October 2025 | London, UK

Conference Brochure

Book Now!

Complimentary Guest Passes are Available

Register

Sponsor

Pioneering The Future Of Biomarkers & Precision Medicine

11 Content Tracks Across Two Days

10+ Hours of pre-arranged 1:1 Meetings

80+ Partners

1,000+ Attendees

Featuring 3 Groundbreaking Programmes!

- **Biomarkers**
- **Spatial Biology for Precision Medicine**
- **Digital Pathology & AI**

Over 150 Industry-Leading Speakers Including...

KEYNOTE SPEAKER

MATTHEW BROWN,
Chief Scientific Officer, Genomics England

Don't Miss His Keynote at 08:45 on Day One:
Improving Rare Disease Diagnostic Performance Using Multiomics

FIRESIDE CHAT

SIR MARK CAULFIELD,
Vice Principal for Health, Faculty of Medicine and Dentistry Queen Mary University of London; Director of the NIHR Barts Biomedical Research Centre; President, British Pharmacological Society

Don't Miss Mark's Fireside Chat at 09:00 on Day Two

PANEL DISCUSSION

IVDR REGULATIONS & THEIR IMPACT

MIKE MESSENGER, Head of Regulatory Strategy, BIVDA
WANDERSON DOS SANTOS TRINDADE, Director Global Regulatory Affairs & CDx, Daiichi-Sankyo
CHRIS BRAY, Head Global Regulatory Affairs, Precision Medicine & Companion Diagnostics, Merck KGaA
VIHANGA PAHALAWATTA, Director Regulatory Affairs Companion Diagnostics, Abbvie
KARIN SCHMITT, Chief Operating Officer, Mursla Bio
SCOTT REID, Vice President & Global Head of Companion Diagnostics, Discovery Life Sciences

Don't Miss the Interactive Panel Discussion on Day One at 11.55

WELCOME TO

Biomarkers & Precision Medicine 2025

Welcome to Biomarkers & Precision Medicine 2025, Oxford Global's premier event that unites the leading minds of Precision Medicine under one roof at the QEII Centre in London on September 30 – October 1.

Join us for two immersive days of expertly curated content tackling the most critical challenges, spotlighting innovation and identifying emerging technologies. Experience 3 cutting edge programmes at an event which is celebrating its 20th Anniversary: Biomarkers 2025, Spatial Biology for Precision Medicine & Digital Pathology & AI.

Engage in high-level discussions and expertly tailored sessions that spotlight breakthroughs across precision medicine. Our carefully designed agenda explores cutting-edge advancements in biomarker-driven research, AI-powered pathology, and spatial multi-omics, shaping the future of diagnostics and therapy development. Join panels of leading scientists as they discuss the integration of spatial insights into biomarker discovery, the role of AI in transforming pathology workflows, and navigating the current regulatory landscape. Sessions will also examine how these innovations enhance clinical decision-making, patient stratification, and drug response monitoring, driving the next wave of precision medicine breakthroughs.

In addition to groundbreaking presentations and interactive discussions, this event offers invaluable networking and interactive opportunities with industry leaders and innovators. Explore our interdisciplinary collaboration hubs, Start-Up Zone and the Plenary Panel Discussions on the exhibition stage.

Don't miss this opportunity to engage with pioneering experts and stay ahead of the next-generation advancements set to redefine precision medicine.

Mike Burden
Director of Production & Content – Precision Medicine Brand,
Oxford Global

Unlock The Latest News & Insights

Sign up for our monthly newsletter to keep up with all things Precision Medicine

Click Here

WHAT'S NEW

Benefits Of Attending

- **Stay ahead of evolving regulatory landscapes and navigate IVDR regulations** with talks, panel discussions and roundtables focused on providing direction to this conundrum.
- **Maximise your time & register for the complementary pre-conference workshop being hosted by Labcorp** on September 29th.
- **Interdisciplinary learning and knowledge share is key to driving Precision Medicine.** Our Collaboration Hub sessions will enable experts and innovators from diverse complementary fields to foster collaboration, hear fresh perspectives, encourage innovation, break down silos and address specific challenges within the field.
- **Gain exclusive insights into cutting-edge biomarker research** - explore the latest in biomarker discovery, validation, and clinical implementation across oncology, neuroscience, immunology, rare diseases etc.
- **Unlock the potential of AI -** discover how AI-powered biomarker analysis, spatial biology, and digital pathology are revolutionising drug development, patient stratification and image analysis.
- **Engage with thought leaders in translational research -** gain firsthand insights from leading scientists, clinicians, and regulatory experts on biomarker adoption, clinical trial design, and strategies for precision medicine implementation.
- **Discover groundbreaking biomarker technologies shaping the future** - deep dive into proteomics, metabolomics, mass spectrometry, flow cytometry, multiplex imaging, and single-cell sequencing techniques advancing biomarker analysis.
- **Delve into biomarker innovations for neurodegenerative diseases & neuroscience** – hear from experts on novel imaging biomarkers, liquid biopsy approaches, and cutting-edge digital biomarker strategies for CNS and neuropsychiatric disorders.

PRECISION MEDICINE AWARDS 2025

Celebrate Your Industry, Acknowledge Your Impact & Accelerate Better Patient Outcomes *At This Night of Celebration At The Stunning Church House Assembly Rooms Just A 3-min Walk Away. The Awards Begin Immediately After The Close of Day One.*

DON'T MISS THESE

Interactive Panels

BIOMARKERS

IVDR Regulations & Their Impact

Biomarker Strategies: Lessons From The Last Decade And The Road Ahead For Pharma & Academia

Translating Biomarkers From Bench To Bedside

Applying Single Cell And Omic Technologies In Biomarker Discovery And Development

Biomarker Strategies In Neurodegenerative Therapeutics

PRECISION MEDICINE

AI-Powered Precision Medicine

Building The Next Era Of Precision Medicine: Stakeholder Collaboration Across Biomarkers, Diagnostics, Omics & Therapeutic Innovation

DIGITAL PATHOLOGY

Building A Business Case For Digital Pathology

Digital Pathology in Pharma – Overcoming Integration Strategies & Future Proofing

SPATIAL BIOLOGY

Addressing The Future Needs Of Spatial Multi-Omics

Utilising Spatial Biology In Pharma R&D

Exploring The Application Of Spatial Technologies In Immunology & Oncology

SPECIAL EVENT FEATURES

Big Attendance Meets Intimate Connections

Special Feature:

PRECISION MEDICINE AWARDS 2025

The celebration event takes place on 30 September at the prestigious Church House Assembly Hall in Westminster, London, following the Biomarkers and Precision Medicine conference.

Join us to celebrate your achievements, light up our industry, and drive the next wave of transformation.

– Day Two –

Keynote Fireside Chat

Join Professor Sir Mark Caulfield for an exclusive fireside chat reflecting on his groundbreaking work and the legacy of his contributions to genomic medicine. In this in-depth conversation, he will share key milestones from his career, the impact of large-scale genomic initiatives, and the lessons learned in advancing precision medicine. Looking ahead, he will offer his perspective on the future of precision medicine, emerging innovations, and the next steps in translating cutting-edge research into real-world clinical practice.

Day One - Opening Keynote Address

Matthew Brown, Chief Scientific Officer, Genomics England

Recognised for his pioneering contributions to genomics and precision medicine, Matthew Brown will take to the stage to explore the transformative potential of multiomics in rare disease diagnostics. He will examine how cutting-edge approaches, including long-read DNA sequencing, transcriptomics, proteomics, and metabolomics, are enhancing diagnostic accuracy beyond traditional short-read whole genome sequencing. With a focus on the latest advancements at Genomics England and across the industry, this keynote will highlight the breakthroughs shaping the future of rare disease research and clinical implementation.

Day One & Two Collaboration Hub Sessions

Interdisciplinary learning and knowledge share is key to driving Precision Medicine. Our Collaboration Hub sessions will provide a platform to enable experts and innovators from diverse complementary fields to foster collaboration, hear fresh perspectives, encourage innovation, break down silos and address specific challenges within the field.

Each invitation-only, focused session will last 50 minutes and with only 15 spaces available per hub, registration is essential to secure your place at the table!

Addressing the Evolving Regulatory Landscape for Personalised Medicine

Moderated by: Vihanga Pahalawatta, Director Regulatory Affairs Companion Diagnostics, Abbvie

Utilising AI in Precision Medicine

Moderated by: James Schofield, Founder & Chief Executive Officer, TopMD Precision Medicine

Bridging the Gap Between Research and Clinical Implementation in Precision Medicine

Moderated by: Richard Barker, Chairman & Founder, Metadvice & New Medicine Partners

Addressing Ethical and Legal Challenges in Genetic Data Use

Moderated by: Natalie Banner, Director of Ethics, Genomics England

WHY PARTNER WITH
OXFORD GLOBAL?

At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

Arrange 1-1 Meetings
Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

Speaking Opportunities
Showcase your company's recent work to a relevant and highly engaged audience.

Host Panel & Roundtable Discussions
Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

Organise Workshops
Demonstrate best practice within the industry in front of your peers with case studies from your clients.

Exhibit your Products & Solutions
Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

Digital Marketing & Lead Generation
Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

LEARN MORE

DRIVE INNOVATION & ACCELERATE RESEARCH

Who Is Partnering?

Diamond Sponsor

labcorp

Gold Sponsors

10x GENOMICS
AKOYA BIOSCIENCES — THE SPATIAL BIOLOGY COMPANY
ALMAC
ariadne.ai
BRUKER
CellCarta
DIAGNEXIA ANALYTIX
DISCOVERY LIFE SCIENCES
IRON MOUNTAIN
Leica MICROSYSTEMS
Luminex
Lunaphore — a biotechne brand
Metabolon
Olink
Personalis
PRECISION for medicine
RULES BASED MEDICINE — an IQVIA business
SAPIENT
STANDARD BIOTOOLS

Silver Sponsors

ARC
biocrates — The future of research and health
BIOIVT — ELEVATING SCIENCE
Burning Rock Dx
CONCEPT LIFE SCIENCES
FOUNDATION MEDICINE
GENSEQ
HOLOGIC Diagenode
Merck
mission bio
Navinci
NEO GENOMICS
OracleBio
Quanterix
seer
SURFIX — Redefining Point-of-Care Testing
synexa | Life Sciences
vizgen
ZEISS

Bronze Sponsors

ALAMAR BIOSCIENCES
BIOGNOSYS — NEXT GENERATION PROTEOMICS
Diaceutics — Better Testing, Better Treatment
HistologiX — Make the most of our expertise
HURDLE
ICON
MEDTECH TO MARKET
Miltenyi Biotec
opentrons
PATHOMATION
RARECYTE
ThermoFisher SCIENTIFIC

Network & Programme Sponsors

AIRA MATRIX
Altheome
Aspect Analytics
ANGLE
BD
BioLizard
biotechne
ESYA
CROWN BIOSCIENCE
Element Biosciences
FINGENIOUS
LEVITAS BIO
NOF CORPORATION
NORDIC BIOSCIENCE
PathQA
Propath — The Spatial Biology CRO
PROSCIA
proteome sciences
QUANTALL
TATAA BIOCENTER
SONRAI
University of Exeter

AGENDA AT A GLANCE

Biomarkers

Join world-leading experts in biomarker research and development for this in-person meeting in the heart of London. Discover groundbreaking insight into biomarker science, patient stratification, companion diagnostics, regulatory considerations, clinical development and trial design and explore cutting-edge innovations driving precision medicine forward.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Biomarkers
- Biomarker Discovery
- Biomarker Identification
- Biomarker Validation
- Clinical Biomarkers
- Pre-Clinical
- Translational Science
- Clinical Development
- Precision Medicine
- Early Detection
- Enabling Technologies
- Multiplex Technologies
- Genomic Biomarkers
- Regulation

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Biomarker Technologies
- Diagnostic Biomarkers
- Imaging Techniques
- Biomarker Analysis
- Proteomics
- Metabolomics
- Clinical Development
- Multiplex tools
- Digital Pathology

Day One

Track 1: Biomarkers Identification, Validation in Oncology, Immuno-Oncology & Immunology

- Biomarker discovery tools and technologies
- Biomarker strategies for patient identification
- Biomarkers to detect, predict and monitor response to treatment
- Check point inhibitors and dual therapies in immuno-oncology

Track 2: Diagnostic Biomarkers & Regulations

- IVDR regulations and their impact
- Companion diagnostic development
- Parallel diagnostic and drug approval strategies
- Diagnostic-driven therapies: towards the clinic with optimised market access and patient adoption

Track 3: Biomarkers for Clinical Development

- Defining a robust clinical biomarker strategy
- Real-world applications of biomarkers in healthcare
- Transforming clinical development through biomarker-driven clinical trial design and data analysis
- Exploratory/clinical endpoint biomarkers needed to support clinical trials
- Biomarker development gene therapy- patient responses and histology

Track 4: Genomic & Multi-Omic Approaches in Biomarker Discovery and Development

- Precision medicine approaches for personalised therapies
- Precision oncology and molecular profiling
- Biofluid-based molecular biomarkers: cfDNA, ctDNA and CTCs
- Validating and verifying genomic markers in preclinical drug development

Day Two

Track 1: Biomarkers Identification & Validation: Neuroscience & Co-Morbidity

- Novel case studies and strategies in biomarker discovery, analysis and validation in neuroscience, CNS, neuropsychiatric disorders
- Imaging, digital and liquid biomarkers
- Technologies and approaches to improve target engagement, early diagnostic biomarkers and how best to incorporate biomarkers into drug development, patient stratification and clinical trials in neuroscience

Track 2: New & Emerging Biomarker Technologies for Biomarker Analysis

- Technology approaches, techniques and analysis - flow cytometry, mass spectrometry, proteomics, metabolomics
- Biomarker assay optimisation and validation
- Single-plex and multiplex technologies
- Integrating multi-omics data

Track 3: Biomarkers for Clinical Trials

- Translational biomarkers from preclinical to clinical phase studies
- The role of safety and efficacy biomarkers in translation
- Patient profiling and biosignatures in clinical development

Track 4: Biomarkers for Diagnostics & Precision Medicine

- Liquid biopsy biomarkers for disease monitoring, multi-cancer screening and early detection /ultra-sensitivity/ MRD
- Latest technologies in detection and molecular characterisation of: CTCs; cfDNA, ctDNA, circulating extracellular RNA; exosomes and microvesicles
- Biofluid biomarkers for early disease detection
- Delivering precision medicine for respiratory, autoimmune, immunology diseases and neuroscience

AGENDA AT A GLANCE

Spatial Biology for Precision Medicine

Join leaders, experts, and researchers in our Spatial Biology for Precision Medicine programme, connecting global academic & research organisations as well as pharma representatives for high-level discussions on the latest innovations in spatial research & technologies.

Forward looking visionary leaders will discuss the current state of the industry, market trends and future growth areas aiding the application of spatial technologies in the clinic as well as the rise of digital pathology.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Spatial Transcriptomics
- Spatial Proteomics
- Systems Biology
- Molecular Medicine
- Spatial Genomics
- Spatial Metabolomics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Spatial Imaging Platforms
- Spatial Data Analysis Tools
- Spatial Genomics
- Tissue Imaging & Prep
- Single Molecule Imaging
- Bioinformatics

Day One

Track 5: Spatial Multi Omics Tools, Techniques & Approaches

- Translating spatial imaging techniques and approaches into clinics
- Transcriptomics, proteomics, genomics and metabolomics breakthrough tools, techniques and approaches for precision medicine
- Single-cell transcriptome / RNA-seq
- Multi-modality processing
- Discovery of robust next-generation diagnostics and biomarkers that are key to designing precision medicine treatments

Track 6: Spatial Biology in Pharma & Translational Drug Research

- Accelerating the discovery and characterisation of biomarkers and drug targets using spatial tools
- Tailoring precision medicine approaches by considering the spatial distribution of drug targets
- Impacting disease research – informing assessment of treatment and action mechanisms/deciphering dynamics of cell interactions
- Feasibility and scalability of various platforms

Day Two

Track 5: AI Image Analysis & Data Analytics In Spatial Biology

- Tissue imaging and analysis using advanced spatial profiling techniques and AI-guided technology
- Imaging data analysis/how to set a spatial experiment
- Relevant spatial parameters in different model systems
- Label-free imaging technologies – imaging mass spec
- Algorithm design for spatial data
- Spatial multiplexed imaging for disease characterisation
- Intersection of Digital pathology and spatial biology
- Computational methods to assist in the identification, classification and visualisation of complex multi-model datasets
- Overcoming challenges in multi-omic data acquisition and analysis

AGENDA AT A GLANCE

Digital Pathology & AI

Gather with leading innovators in digital pathology for an in-person event in the heart of London.

Dive into the latest advancements in AI-driven image analysis & computational pathology, as well as hearing from the challenges faced and lessons learnt from those who have already implemented DP & AI into their workflow so that you can join others in shaping the future of pathology.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Digital Pathology
- Computational Pathology
- Image analysis
- Biomedical Informatics & AI
- Computational Medicine
- Pathology IT
- Immunohistochemistry
- Histopathology
- Toxicology and Safety Sciences
- NHS transformation
- Pathology
- Diagnostics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Digital Pathology Hardware
- Scanners
- Monitors
- Digital Pathology Software
- Image analysis
- Multi-modal image analysis
- Image Management
- Cloud computing/ storage
- End to End Solutions
- LIS
- Enterprise Imaging & Healthcare IT
- AI Algorithms

Day One

Track 7: Digital Pathology Implementation - Image Analysis & AI

- Advances, challenges, benefits and future developments of Digital Pathology, and the implications for pathology practice
- Analysing the business case for digital pathology
- User experience of converting to and integrating digital pathology
- Advances in image quality and processing
- Interoperability – fully integrated DP and AI workflow
- Integrating pathology data with molecular data for accurate diagnosis and personalised treatment
- Exploring both manual and fully automated image analysis and pattern recognition
- Pathologists' perspective – using and working with AI
- Image format standardisation
- Multiplexed image analysis

Day Two

Track 6: Computational Pathology & Utilising Digital Pathology In Pharma Research

- Implementing AI-based precision pathology
- AI-assisted diagnosis to improve the efficiency of pathologists
- Advancing machine and deep learning algorithms
- Improving WSI workflow efficiency
- Pathology PACS and informatics
- Data Storage – addressing the challenge
- Computational Pathology in Precision Oncology
- Ground truth data and technology for biomarker assessment
- Digital image analysis in drug discovery
- Digitising toxicology
- AIML solutions for Biomarker discovery, detection, quantification and use in patient selection

ALL PROGRAMMES

Confirmed Speakers

KEYNOTE SPEAKERS

MARIA ORR,
Head of Precision Medicine, Biopharmaceuticals, AstraZeneca

MICHAEL CANNARILE,
Head of Biomarkers, Early Development Oncology (EDO), Pharma Research & Development (pRED), Roche Innovation Center Munich

MIKE MESSENGER,
Head of Regulatory Strategy, BIVDA

PAUL J VAN DIEST,
Professor and Head, Department of Pathology, University Medical Center Utrecht

VIHANGA PAHALAWATTA,
Director Regulatory Affairs Companion Diagnostics, Abbvie

BERND WOLLSCHEID,
Head of Institute for Translational Medicine, Professor & Group Head, ETH Zurich

VIRGINIA SAVOVA,
Senior Director, Cell Targeted Precision Medicine, AstraZeneca

ALEXANDRA SEVKO
VP of Translational Science, Amphista Therapeutics

ALAIN VAN GOOL
Professor of Personalised Healthcare, Radboud University Medical Centre

AMONIDA ZADISSA
Associate Director of Informatics, UK Dementia Research Institute

ANTONINA MITROFANOVA
Associate Dean for Research & Associate Professor, Department of Biomedical and Health Informatics, Rutgers University

ARMAN RAHMAN
Assistant Professor of Anatomy, University College Dublin

ARTHUR LEWIS
Director of Pathology, Clinical Pharmacology & Safety Sciences, AstraZeneca

AZAM HAMIDINEKOO
Associate Director of Clinical Pharmacology & Safety Sciences, AstraZeneca

BELINDA NEDJAI
Associate Professor in Cancer Biomarkers & Epigenetics, Director of Molecular Epidemiology Laboratory, Queen Mary University of London

BERND WOLLSCHEID
Head of Institute for Translational Medicine, Professor & Group Head, ETH Zurich

CHRIS BRAY
Head of Global Regulatory Affairs, Precision Medicine & Companion Diagnostics, Merck KGaA

DANNY KAYE
Lead Digital Pathology Scientist, Leeds Teaching Hospitals NHS Trust, NPIC

DAVID CLARK
Consultant Haematopathologist, Nottingham University Hospitals NHS Trust

DAVID KRIGE
Head of Translational Sciences, Accession Therapeutics

DAVID SNEAD
Professor & Consultant Pathologist UHCW NHS Trust Coventry and Director of PathLAKE

DEBAYAN MUKHERJEE
Principal Scientist of Spatial Multiplex Imaging, In Vitro/In Vivo Translation Research, Pharma R&D, GSK

EDINA SILAJDZIC
Lecturer, King's College London

ELIZABETH HARRINGTON
Global Head of Translational Medicine, Targeted Therapy Franchise, AstraZeneca

ELENA MIRANDA
Director of Non-Clinical Histology, GSK

EMANUELA OLDONI
Scientific Lead of Personalised Medicine, EATRIS, European Infrastructure for Translational Medicine

EMMANUEL VALENTIN
Vice President of Translational Medicine, ImCheck Therapeutics

ESPEN WALKER
Global Head of Medical Diagnostics, AstraZeneca

FAN LIU
Professor & Group Head, FMP Berlin

FRANCESCA TRAPANI
Scientific Director of Molecular Pathology & Laboratory Head, Boehringer Ingelheim

GAYLE MARSHALL
Head of Biomarkers, Medicines Discovery Catapult

GIOVANNA LALLI
Director of Strategy & Operations, Life Arc

HARPREET SAINI
Senior Director of Bioinformatics, Astex Therapeutics

HELEN GRAVES
Principal Scientist, Alchemab Therapeutics

HENOCH HONG
Associate Director, Merck KGaA

HUW BANNISTER
Senior Director of Global Diagnostics, Digital & Computational Pathology, AstraZeneca

INÊS SEQUEIRA
Associate Professor, Group Leader, Spatial Biology Hub Lead, Queen Mary University London

IRENE DEL MOLINO DEL BARRIO
Principal Scientist, GSK

JAN-PHILIPP MALLM
Head of Single Cell Open Lab, DKFZ, German Cancer Research Center

JEAN-BAPTISTE LUGAGNE
Associate Professor, University of Oxford

JEAN-CHRISTOPHE OLIVO-MARIN
Professor & Head of the Quantitative Image Analysis Unit, Institut Pasteur

JENS KIECKBUSCH
Director of External Innovation, Precision Medicine, Research & Development, GSK

JIMMY BELL
Professor & Director, Research Centre for Optimal Health, University of Westminster

JIM EYLES
Director of Clinical Immuno-Oncology Discovery Group, AstraZeneca

JO TAYLOR (BEM)
Founder, After Breast Cancer Diagnosis & METUPUK

JOANNA JANUS
Research Programme Manager (Early Detection & Prevention), Cancer Research UK

ALL PROGRAMMES

Confirmed Speakers

JOÃO PINTO
Medical Specialist, Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup)

JOHAN LUTHMAN
Executive Vice President and Head of R&D, Lundbeck

JEROEN VAN DER LAAK
Professor of Computational Pathology, Radboud University

JOSHUA ATKINS
Senior Genomic Epidemiologist, Cancer Epidemiology Unit (CEU), University of Oxford

KARL SMITH-BYRNE
Senior Molecular Epidemiologist, Cancer Epidemiology Unit (CEU), University of Oxford

KARIN SCHMITT
Chief Operating Officer, Mursla Bio

KAZUMASA KANEMARU
Postdoctoral Researcher, Teichmann Group, Cambridge Stem Cell Institute, University of Cambridge

KIRI GRANGER
Chief Scientific Officer, Monument Therapeutics

KRISTINA HOLMBERG
Head of Clinical Biomarkers, Lundbeck

LAURENT AUDOLY
Chief Executive Officer & Co-Founder PriveBio, Inc

MANI MUDALIAR
Director of Quantitative Biomarkers, Recursion

MANUELA CERINA
Scientific Director of Neurodegeneration, LifeArc

MANUEL SALTO-TELLEZ
Professor of Integrative Pathology & Director of Integrated Pathology Unit (IPU), Institute of Cancer Research

MARÍA LAURA GARCIA BERMEJO
Scientific Director & Co-chair, Ramon & Cajal Health Research Institute (IRYCIS) & EATRIS Biomarkers Platform

MARISCA MARIAN
Oncology Market Access Strategy Leader, Bayer

MARIA ORR
Head of Precision Medicine, Biosamples & Early Oncology, AstraZeneca

MARIYA IVANOVSKA
Chief Assistant Professor, The Medical University of Plovdiv

MARKUS SCHULZE
Senior Scientist of Clinical Biomarkers and Technologies, Merck Healthcare KGaA

MATTHEW BROWN
Chief Scientific Officer, Genomics England

MATTHEW HUMPHRIES
Director of Research Operations, Leeds Teaching Hospitals NHS Trust

MICHAEL CANNARILE
Head of Biomarkers, Early Development Oncology (EDO), Pharma Research & Development (pRED), Roche Innovation Centre Munich

MICHAEL ZAIAC
Head of Medical Affairs & Oncology, Europe & Canada, Daiichi Sankyo

MIGUEL SOUTO MORA
Director of Business Development & Innovation, IDIBELL

MIKE MESSENGER
Head of Regulatory Strategy, BIVDA

MIRO VENTURI
Operating Partner, ARCHIMED

MUHAMMAD ASLAM
Consultant Pathologist, National Clinical Lead for Digital Pathology & AI, Wales, Betsi Cadwaladr University Health Board

NATALIE BANNER
Director of Ethics, Genomics

NEIL HUMPHRYES-KIRILOV
Associate Director of Human Genomics, C4X Discovery

NIK MATTHEWS
Head of Imperial BRC Genomics Facility, Imperial College London

NITIN JAIN
Director of Franchise Project Management, AstraZeneca

OLGA NISSAN
CEO, Protica Bio

PAUL J VAN DIEST
Professor & Head, Department of Pathology, University Medical Center Utrecht

PETER GROENEN
Head Of Translational Science, Owner & Consultant, Cerebrum DAO & Alpinuity Bio GmbH

RAHUL DEB
Consultant Histopathologist & Lead Breast Pathologist, University Hospitals of Derby & Burton

RICHARD FESTENSTEIN
Clinical Professor of Molecular Medicine, Department of Brain Sciences, Imperial College London

SIR MARK CAULFIELD
Vice Principal for Health, Faculty of Medicine and Dentistry, Queen Mary University of London; Director of the NIHR Barts Biomedical Research Centre; President, British Pharmacological Society

SONALI NATU
Consultant Cellular Pathologist, Tees Valley Pathology Services & Clinical Lead for Pathology, North East and North Cumbria

SVETLANA MUKHINA
Director of Global Regulatory Affairs, CDx, Merck Healthcare KGaA

STEPHANIE CRAIG
Lecturer in Precision Medicine, Queen's University Belfast

THOMAS HACH
Global Programme Clinical Head, Novartis

THOMAS JENSEN
Chief Executive Officer, Allarity

VALERIE TALY
CNRS Research Director & Group Leader, University of Paris Descartes

VICTORIA GOSS
Head of Early Diagnosis and Translational Group, University of Southampton Clinical Trials Unit

VIHANGA PAHALAWATTA
Director of Regulatory Affairs Companion Diagnostics, Abbvie

VIRGINIA SAVOVA
Senior Director of Cell Targeted Precision Medicine, AstraZeneca

WANDERSON DOS SANTOS TRINDADE
Director of Global Regulatory Affairs & Companion Diagnostics, Daiichi-Sankyo

WOLFGANG BREITWIESER
Head of Molecular Biology, Cancer Research UK Manchester Institute

WOUTER DE JONGE
Professor of Neurogastroenterology, Amsterdam UMC

Registration Required Sessions

Pre Event Workshop | Hosted by Labcorp - 29 September 2025

Empowering Precision Medicine with Comprehensive Insights and Global Scalability

This workshop offers a deep dive into accelerating precision medicine programmes, reducing development risks, and enhancing successful outcomes using insights across various therapeutic areas.
Attendees will gain valuable insights into maximising ROI in biomarker-driven development and learn from industry experts sharing real-world success focused on:

- Balancing scientific innovation with operational efficiency
- Scientific and operational strategies to enhance global reach and adoption
- Optimising study design for enhanced outcomes in critical therapeutic areas, including oncology, neurology, cardiometabolic and rare diseases, using novel biomarkers
- Leveraging the right technology platform in key areas such as flow cytometry, digital pathology, and next-generation sequencing to advance immune profiling, enable AI-generated insights and unlock new genomic targets

By attending, participants will gain a comprehensive understanding of the latest trends, challenges, and opportunities in precision medicine, equipping them with the knowledge to accelerate patient access to critical therapeutics while navigating the complexities of biomarker-driven development.

labcorp

13:00 **Registration & Networking**

13:30 **Welcome -** LUCAS RIFKIN, MD Senior Medical Director, Medical Affairs, Labcorp

13:45 **Therapeutic Area Application: Insights into Novel Clinical Biomarkers for MASH -** SANDRA LJUBICIC, MSc, PhD Senior Scientist, Cardiometabolic Biomarkers, Biomarker Solution Center, Labcorp

14:15 **Therapeutic Area Application: The Role of NGS in Clinical Trials for Next- Generation Therapies -** TAYLOR JENSEN, PhD VP, Head of Science Enterprise Oncology, Labcorp

14:45 **Break**

15:15 **Current Landscape and Future Perspectives for the Role of Flow Cytometry in Drug Development, From Biomarker Discovery to Personalized Medicine -** CHRISTÈLE GONNEAU, PhD Global Scientific Director, Flow Cytometry, Labcorp

15:30 **Advancing Biomarker Discovery in Clinical trial through Digital Pathology and Artificial Intelligence -** PAUL MESANGE, PhD Global Director of Operations, Histology, Labcorp

15:45 **Effective Personalized Medicine and Disease Monitoring with Circulating DNA Biomarkers -** ALEX FORT, PhD Lead Scientist, Genomics, Labcorp

16:00 **Q&A Panel**

16:30 **Blueprint for Companion Diagnostics: Translating biomarker Insights -** TUC AHMAD, Scientific Director, Diagnostic Development Services, Labcorp

16:50 **Closing -** LUCAS RIFKIN, MD Senior Medical Director, Medical Affairs, Labcorp

17:00 **End of workshop**

Registration Required Sessions

Collaboration Hub Sessions Day 1 - 30 September 2025

11:25 - 12:15

Bridging the Gap Between Research and Clinical Implementation in Precision Medicine

- Discussion Points: Identifying the barriers to translating research findings into clinical practice and exploring strategies to improve collaboration and align academic research with clinical needs, regulatory requirements and healthcare systems
- Invited Specialists: Academic researchers, clinicians, healthcare administrators, technology or knowledge transfer, regulatory officials and translational medicine experts

Moderated by: RICHARD BARKER, Chairman & Founder, **Metadvice & New Medicine Partners**

14:35 - 15:25

Addressing Ethical and Legal Challenges in Genetic Data Use

- Discussion Points: How to create ethical guidelines and legal frameworks for responsible genetic data use in precision medicine
- Invited specialists: Bioethicists, legal experts, geneticists, patient advocates, government policy makers

Moderated by: NATALIE BANNER, Director of Ethics, **Genomics England**

15:25 - 16:15

Addressing the Evolving Regulatory Landscape for Personalised Medicine

- Discussion Points: How to prepare for and adapt to shifts in regulations related to personalised health care, whilst streamlining processes
- Invited Specialists: Regulatory officials, patient representatives, clinicians

Moderated by: VIHANGA PAHALAWATTA, Director of Regulatory Affairs & Companion Diagnostics, **Abbvie**

Collaboration Hub Sessions Day 2 - 01 October 2025

11:20 - 12:10

Overcoming Barriers to Technology Adoption/Transfer in Precision Medicine

- Discussion Points: How to align stakeholders and design strategies to overcome the challenges in adopting precision medicine technologies, such as cost, accessibility, technology transfer and integration into clinical workflows
- Invited specialists: Technology developers, implementation specialists, knowledge/ technology transfer, healthcare administrators, clinicians and regulatory officials

Moderated by: ADAMA IBRAHIM, Vice President of Digital Transformation, Research and Early Development (R&D), **Novo Nordisk**

12:10 - 13:00

Utilising AI in Precision Medicine

- Discussion Points: How to maximise the benefit of AI in precision medicine and explore challenges around managing risk, ethical considerations, regulatory compliance and integrating into existing systems
- Invited Specialists: AI specialists, data scientists, clinicians, regulatory officials, bioethicists and IT infrastructure experts

Moderated by: James Schofield, Founder & Chief Executive Officer, **TopMD Precision Medicine**

14:50 - 15:40

Integrating and Sharing Data in Precision Medicine

- Discussion Points: Designing strategies to improve integration and analysis of diverse data sources (genomics, proteomics, patient health records) and also the sharing of datasets internally and externally to further precision medicine research
- Invited Specialists: Data scientists, bioinformaticians, clinicians and IT infrastructure experts

Moderated by: TBA

Day One | 30 September 2025

07:40 **Registration Opens**

08:40 **Oxford Global's Welcome Address**

08:45 **Exhibition Room - Plenary Keynote Address - Improving Rare Disease Diagnostic Performance Using Multiomics**

- Short-read whole genome sequencing provides genetic diagnoses for about 30% of patients referred with rare diseases. Although many of these patients will have oligo- or polygenic diseases, or diseases of environmental origin.
- Many patients with monogenic diseases are thought to remain undiagnosed using this single technology approach.
- New approaches, including long-read DNA sequencing, transcriptomics, proteomics and metabolomics have potential to provide diagnoses for a significant proportion of those where short-read sequencing is not diagnostic.
- Future perspectives at England and wider industry.

MATTHEW BROWN, Chief Scientific Officer, **Genomics England**

BIOMARKERS & PRECISION MEDICINE

CONF ROOM 1: WESTMINSTER - BIOMARKER IDENTIFICATION, VALIDATION, IN ONCOLOGY, IO & IMMUNOLOGY

Track Chair: Deepak Bhere, Assistant Professor & Principal Investigator, **University of South Carolina**

Track Keynote Address: Biomarker Strategies For Patient Identification

09:15 MICHAEL ZAIAC, Head of Medical Affairs, Oncology, Europe & Canada, **Daiichi Sankyo**

CONF ROOM 2: ST JAMES - DIAGNOSTIC BIOMARKERS & REGULATIONS

Track Chair: EVA RODRIGUEZ-SUAREZ, Biomarker Lead/ Biomarker Strategy Immunology, **Novartis**

Track Keynote Address: CDx Regulatory Framework In The US And EU

While companion diagnostics help to identify the best treatment options for patients, their development represents a major challenge due to the complexity of regulatory requirements and demands efficient coordination between drug developers, IVD companies and Health Authorities. This presentation shares the perspective from a Pharma company on the regulatory strategy that enables successful drug/ CDx co-development and co-approval in the US and EU.

SVETLANA MUKHINA, Director of Global Regulatory Affairs & CDx**, Merck Healthcare KGaA**

CONF ROOM 3: MOORE - BIOMARKERS FOR CLINICAL DEVELOPMENT

Track Chair: Alex Dulovic, Group Leader, **NMI**

Track Keynote Address: The Impact Of Biomarkers In Early Clinical Trial Design And Decision Making

Decision-making for new molecular entities in early clinical development often suffers from the risk of false positive and negative decisions driven by small heterogeneous, and often advanced stage patient populations. This talk will explore how biomarker concepts can mitigate such risks by enhancing patient enrichment, supporting dose selection, and demonstrating evidence of mechanism in Phase I clinical development.

MICHAEL CANNARILE, Head of Biomarkers, Early Development Oncology (EDO), Pharma Research & Development (pRED), **Roche Innovation Centre Munich**

CONF ROOM 4: ABBEY - GENOMIC & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT

Track Chair: Jose Izarzugaza, Director, Biomarker & MoA Insights, **Novo Nordisk**

Track Keynote Address: Precision Medicine, Proteomics And Problem Solving

- Why genetics are not enough?
- Examples and limitations of proteomics in common and rare diseases
- How can academia, industry, patients and regulators (alphabetically listed) find pragmatic solutions?

THOMAS HACH, Global Programme Clinical Head, **Novartis**

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONF ROOM 5: GIELGUD & BURTON - SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Track Chair: Nik Matthews, Head of Imperial BRC Genomics Facility, **Imperial College London**

Track Keynote Address: Spatial Multiplex & Transcriptomics Applications In Drug Discovery

Advances in multiplexing and computational analysis have revolutionised our comprehension of tissue-specific biology and therapeutic interactions. Spatial multiplexing facilitates drug discovery by characterising patient biopsies, elucidating model systems, and identifying novel biomarkers. It also contributes to understanding drug distribution, molecular heterogeneity, and the mechanisms underlying off-target toxicity. This presentation provides an overview of recent developments in the field, along with examples from projects.

ELENA MIRANDA, Director of Non-Clinical Histology, **GSK**

CONF ROOM 6: OLIVIER - SPATIAL BIOLOGY IN PHARMA & TRANSLATIONAL DRUG RESEARCH

Track Chair: Stephanie Traub, Associate Director, BSM & Biomarker Lead, **UCB**

Track Keynote Address: Cell-Cell Interaction And Tissue Architecture In Health And Disease

Cell-cell interactions and tissue architecture are crucial in maintaining health, influencing cellular behavior and tissue homeostasis. Disruptions in these interactions contribute to disease pathogenesis, including cancer and autoimmune disorders. Understanding these dynamics can reveal mechanisms of disease and identify therapeutic targets, highlighting the interplay between cellular microenvironments and tissue architecture as pivotal in health and disease management.

VIRGINIA SAVOVA, Senior Director of Cell-Targeted Precision Medicine, **AstraZeneca**

DIGITAL PATHOLOGY & AI

CONF ROOM 7: RUTHERFORD - DIGITAL PATHOLOGY IMPLEMENTATION - IMAGE ANALYSIS & AI

Track Chair: Jean-Christophe Olivo-Marin, Professor & Head of the Quantitative Image Analysis Unit, **Institut Pasteur**

Conference Room 7 Track Keynote Address: AI Implementation: Who Pays The bills?

The possibilities for clinically using AI in daily diagnostic pathology are rapidly increasing with many good algorithms that are brought to the market, often with certification. However, implementation is not taking off rapidly for two main reasons: implementation is technically still challenging, and the business case needs to be developed. In this presentation, the ins and outs of the business case for AI implementation in pathology will be discussed.

PAUL J VAN DIEST, Professor and Head, Department of Pathology, **University Medical Centre Utrecht**

Q&A session & transition time between conference rooms

Day One | 30 September 2025

	BIOMARKERS & PRECISION MEDICINE				SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI
	CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION, VALIDATION, IN ONCOLOGY, IO & IMMUNOLOGY	CONF ROOM 2: **ST JAMES** - DIAGNOSTIC BIOMARKERS & REGULATIONS	CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL DEVELOPMENT	CONF ROOM 4: **ABBEY** - GENOMIC & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT	CONF ROOM 5: **GIELGUD & BURTON** - SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES	CONF ROOM 6: **OLIVIER** - SPATIAL BIOLOGY IN PHARMA & TRANSLATIONAL DRUG RESEARCH	CONF ROOM 7: **RUTHERFORD** - DIGITAL PATHOLOGY IMPLEMENTATION - IMAGE ANALYSIS & AI
09:40	**Liquid Biopsy-Based Opportunities To Accelerate Solid Tumor Drug Development Strategies** labcorp Overview of circulating tumor DNA approaches to address the solid tumor cancer care continuum Circulating tumor DNA strategies to complement radiographic and survival-based endpoints in patients with advanced and metastatic cancer Molecular residual disease analyses for risk stratification in patients undergoing curative intent intervention TAYLOR JENSEN, VP, Head of Science Enterprise Oncology, **Labcorp**	**Diamond/Platinum Level Solution Provider** *Attendees Are Welcome To Attend Co-Located Sessions*	**The Application Of Metabolomics On The AMBROSIA Cohort To Understand ALS** Metabolon PROF. DAME PAMELA SHAW, Professor of Neurology, Director of the Sheffield Institute for Translational Neuroscience (SITraN), Director NIHR Sheffield Biomedical Research Centre, **University of Sheffield**	**Building A Proteomic Landscape With SomaScan®** STANDARD BIOTOOLS The SomaScan Platform provides the largest number of protein measurements and the greatest number of orthogonally confirmed protein reagents in the proteomics industry. It offers 11,000 protein measurements simultaneously from sample volumes as low as 55 µl, giving researchers access to half of the human proteome in just one assay. This presentation will provide an overview of the SomaScan proteomics platform along with example case studies on how it can be used to understand biology and provide valuable information on disease and disease progression. Senior Representative, **Standard Biotools**	**Spatial Multiomics To Reshape Translational And Clinical Research** Lunaphore a biotechne brand Spatial biology advances precision medicine by localising biomarkers. Lunaphore's COMET™ platform applies seqIF™ with standard antibodies to generate reproducible spatial proteomics data. We present a multiomics workflow combining RNAscope™ and seqIF™, a multiplex immunotherapy panel, and analysis tools to characterise immune cells in melanoma. A CellCarta guest speaker will showcase COMET™ in clinical trials, highlighting validated biomarker detection to support targeted therapies. EIRINI LAMPRAKI, Product Marketing Manager, **Lunaphore** ELIZABETH ROSS, Director of Scientific Business Development, **CellCarta**	**Ariadne.ai SPATIAL - Unlocking Neuroscience Applications In Spatial Omics** ariadne.ai SPATIAL offers browser-based access to ariadne.ai's best-in-class models for cell and tissue segmentation, artefact suppression and marker positivity mapping. In this presentation, we'll focus particularly on the applications that precise cell segmentation unlocks in neuroscience, and the use of scalable elastic registration in sequential chromogenic IHC. FABIAN SVARA, CEO **Ariadne AI**	**Solution Provider Presentation** IRON MOUNTAIN® VANDANA MALLEMPATI, Senior Director of Product Management, **Iron Mountain**
10:05	**MORNING NETWORKING BREAK & REFRESHMENTS:**	Poster Displays & 1-2-1 Meetings x4					

Day One | 30 September 2025

BIOMARKERS & PRECISION MEDICINE

CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION, VALIDATION, IN ONCOLOGY, IO & IMMUNOLOGY

From Concept to Clinic: The Emerging Role Of Next Generation Multi-Omics In Biomarker-Driven Drug Development

SAPIENT

- How mass spectrometry offers a single platform for multi-omics analyses of dynamic proteins, metabolites, and lipids across sample matrices, species, and development phases
- How these approaches de-risk and accelerate translation of known and novel drug targets and biomarkers, from target identification to clinical assays
- How Sapient's DynamiQ™ Insights Engine provides a clinical and molecular reference database to strengthen decision confidence by validating findings across diverse populations

MO JAIN, Founder and Chief Scientific Officer
Sapient

CONF ROOM 2: **ST JAMES** - DIAGNOSTIC BIOMARKERS & REGULATIONS

Running The CDx Gauntlet: Developing A Commercial Ready CDx, Navigating IVDR, And Preparing For Market Access

DISCOVERY

- Overview of developing prototype companion diagnostics, balancing early trial performance with commercialisation, illustrated through case studies
- Use of LDTs to reduce costs and timelines, with compliance to IVDR, UKCA, and FDA requirements supported by our Kassel laboratory
- Pathways to transition from LDTs to commercial CDx solutions, accelerating patient sample access and ensuring readiness for market launch

SCOTT REID, VP & Global Head of Companion Diagnostics,
Discovery Life Sciences

CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL DEVELOPMENT

Solution Provider Presentation

Personalis

Senior Representative,
Personalis

CONF ROOM 4: **ABBEY** - GENOMIC & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT

Solution Provider Presentation

mission bio

Senior Representative,
Mission Bio

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONF ROOM 5: **GIELGUD & BURTON** - SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Scaling Spatial Biology With The Phenocode™ IO60 Panel: Real-World Experience From Propath

AKOYA BIOSCIENCES
THE SPATIAL BIOLOGY COMPANY®

During this session, Akoya Biosciences (A Quanterix Company) will present the PhenoCode™ IO60 panel, an ultrahigh-plex solution for deep spatial phenotyping of the tumor microenvironment. Kelly Hunter, Chief Scientific Officer at Propath, a scientifically driven CRO with extensive wet and dry lab expertise, will share his experience automating IO60 for scalability. Together, Akoya and Propath will highlight how automation and scientific partnership enable reproducibility, accelerate translational research, and generate actionable biological insights.

KELLY HUNTER, Chief Scientific Officer,
Propath UK

CONF ROOM 6: **OLIVIER** - SPATIAL BIOLOGY IN PHARMA & TRANSLATIONAL DRUG RESEARCH

Maximise Insights, Maximise Success: Shaping the Future Of Biomarker Development With 10x Genomics Single Cell And Spatial Technologies

10x GENOMICS

10x Genomics accelerates biopharma research with single cell, spatial, and in situ multiomics- advancing drug development, biomarker discovery, and translational insights. This presentation will highlight our key technologies and latest innovations.

Senior Representative,
10x Genomics

DIGITAL PATHOLOGY & AI

CONF ROOM 7: **RUTHERFORD** - DIGITAL PATHOLOGY IMPLEMENTATION - IMAGE ANALYSIS & AI

Pixels with Purpose: Advancing Precision Medicine With Digital Pathology

labcorp

Precision medicine demands more than just targeted therapies—it requires targeted tools. Digital pathology is emerging as a critical enabler in identifying, validating, and operationalizing biomarkers that drive patient stratification and therapeutic success. In this session, we'll share how AI-powered image analysis, multiplex imaging, and robust data platforms to deepen biological understanding and accelerate drug development. Through concrete examples, we'll demonstrate how digital pathology workflows can integrate seamlessly into biomarker discovery and companion diagnostic programs.

PAUL MESANGE, Global Director of Histology,
Labcorp

11:25

Day One | 30 September 2025

BIOMARKERS & PRECISION MEDICINE

CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION, VALIDATION, IN ONCOLOGY, IO & IMMUNOLOGY

Transforming Cancer Patient Management Through Digital Pathology And Spatial Profiling

This talk highlights how digital pathology and spatial profiling can potentially revolutionise care for Head and Neck Squamous Cell Carcinoma (HNSCC). To address overtreatment driven by limited biomarkers, we explore single-cell spatial multiomics for novel prognostic and predictive marker discovery. Biomarkers to segregate patients into high- and low-risk recurrence groups can guide personalised therapy and improve outcomes.

ARMAN RAHMAN, Assistant Professor of Anatomy, **University College Dublin**

CONF ROOM 2: **ST JAMES** - DIAGNOSTIC BIOMARKERS & REGULATIONS

IVDR Performance Evaluation - A Roadmap For Innovators

This talk will provide a strategic roadmap for innovators navigating performance evaluation under the EU IVDR. It will introduce the core pillars of scientific validity, analytical performance, clinical performance, and human factors, outlining key frameworks for compliance. Through practical insights and case examples, we will explore how to optimise efficiency, reduce costs, and streamline timelines in regulatory submissions.

MIKE MESSENGER, Head of Regulatory Strategy, **BIVDA**

CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL DEVELOPMENT

Building An Early Diagnosis Trial Group: Previous, Current And Future Studies

In July 2023, the Southampton Clinical Trials Unit established a dedicated Early Diagnosis and Translational Group to support the increasing number of studies in this field.This talk will provide an overview of these trials and share first-hand insights into the highs and lows of running studies in early diagnosis and translation.

VICTORIA GOSS, Head of Early Diagnosis and Translational Group, **University of Southampton Clinical Trials Unit**

CONF ROOM 4: **ABBEY** - GENOMIC & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT

Precision Phenotyping For Precision Medicine

By using in-depth MRI-based phenotyping we are enabling precise, non-invasive assessment of organ structure and function. This approach supports the development of novel biomarkers to stratify disease risk, guide early diagnosis, tailor treatments, and optimise clinical trial design. By integrating rich imaging-derived phenotypes into precision medicine, we advance predictive, preventive, and therapeutic strategies across diverse patient populations.

JIMMY BELL, Professor & Director, Research Centre for Optimal Health, **University of Westminster**

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONF ROOM 5: **GIELGUD & BURTON** - SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Spatial Omics Technologies In A Cancer Research Facility

Spatial omics processing involves complex workflows requiring sophisticated skills in histology, molecular biology, as well as scientific computing and bioinformatics.In our institute, for handling spatial transcriptomics projects, multiple core facilities provide a comprehensive service that includes all aspects of sample processing including tissue QC, staining and imaging, region selection and capture, followed by library prep, sequencing and data processing using dedicated computational pipelines.

WOLFGANG BREITWIESER, Head of Molecular Biology, **Cancer Research UK Manchester Institute**

CONF ROOM 6: **OLIVIER** - SPATIAL BIOLOGY IN PHARMA & TRANSLATIONAL DRUG RESEARCH

Approaches To Leverage Spatial Biology And Machine Learning For Clinical Biomarker Development

- The importance of spatial context in drug development
- Spatial context and antibody drug conjugates (ADCs)
- Derivation of context information from H&E images using machine learning: Tumor micro-environment and HRD
- Resolving spatial context by multiplex immunofluorescence

MARKUS SCHULZE, Senior Scientist of Clinical Biomarkers & Technologies, **Merck Healthcare KGaA**

DIGITAL PATHOLOGY & AI

CONF ROOM 7: **RUTHERFORD** - DIGITAL PATHOLOGY IMPLEMENTATION - IMAGE ANALYSIS & AI

Transforming Cellular Pathology At Nottingham University Hospitals - Delivering 100% Digital Pathology Reporting And Integrating AI Into Routine Diagnostic Practice

Nottingham University Hospitals (NUH) cellular pathology is one of the largest acute teaching hospital trusts in the NHS. The department has implemented Indica labs HALO AP digital pathology system. 100% of cases are scanned and reported with a completely digital workflow. Pathologists work in a paperless, glassless virtual workspace. AI tools have been integrated into the routine clinical workflow including the IBEX Galen prostate and breast tools and the Indica labs Macrodissect tools. This presentation will describe the implementation journey, outcomes and lessons learned.

DAVID CLARK, Consultant Haematopathologist, **Nottingham University Hospitals NHS Trust**

11:50

Q&A session & transition time between conference rooms

Day One | 30 September 2025

BIOMARKERS & PRECISION MEDICINE

CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION, VALIDATION, IN ONCOLOGY, IO & IMMUNOLOGY

12:15

Panel Discussion:
Biomarker Strategies: Lessons From The Last Decade And The Road Ahead For Pharma & Academia

Moderator:
EMANUELA OLDONI, Scientific Lead of Personalised Medicine, **EATRIS, European Infrastructure for Translational Medicine**

Panellists:
ALAIN VAN GOOL, Professor of Personalised Healthcare, **Radboud University Medical Centre**

MARÍA LAURA GARCIA BERMEJO, Scientific Director & Co-chair, **Ramon & Cajal Health Research Institute (IRYCIS) & EATRIS Biomarkers Platform**

PETER GROENEN, Head Of Translational Science, Owner & Consultant, **Cerebrum DAO & Alpinuity Bio GmbH**

MIGUEL SOUTO MORA, Director of Business Development & Innovation, **IDIBELL**

PAUL RHYNE, Senior Director of Scientific Solutions, **Luminex**

KIRI GRANGER, Chief Scientific Officer, **Monument Therapeutics**

INTERACTIVE

12:40

CONF ROOM 2: **ST JAMES** - DIAGNOSTIC BIOMARKERS & REGULATIONS

Panel Discussion:
IVDR Regulations & Their Impact

Moderator:
MIKE MESSENGER, Head of Regulatory Strategy, **BIVDA**

Panellists:

WANDERSON DOS SANTOS TRINDADE, Director of Global Regulatory Affairs & CDx, **Daiichi-Sankyo**

CHRIS BRAY, Head of Global Regulatory Affairs, Precision Medicine & Companion Diagnostics, **Merck KGaA**

VIHANGA PAHALAWATTA, Director of Regulatory Affairs Companion Diagnostics, **Abbvie**

SCOTT REID, Vice President & Global Head of Companion Diagnostics, **Discovery Life Sciences**

KARIN SCHMITT, Chief Operating Officer, **Mursla Bio**

INTERACTIVE

CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL DEVELOPMENT

Start-Up Zone Pitches

10-Minute Presentation:
DoMore Diagnostics

10-Minute Presentation 2
The Third Dimension For Histology

- True multimodal continuity: image first, then IHC/omics on the same block
- Non-destructive 3D on standard FFPE blocks
- Access anywhere: secure browser-based 3D viewer (desktop/tablet) plus exports for downstream analysis

JENS HANSEN, Co-Founder & Chief Commercial Officer, **Histomography**

10-Minute Presentation 3
Beacon Scientific Consulting

10-Minute Presentation 5
Physio Activity

10-Minute Presentation 4
Nexomic

CONF ROOM 4: **ABBEY** - GENOMIC & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT

Panel Discussion:
Applying Single Cell & Omic Technologies In Drug Discovery And Development

- Current challenges: extracting meaningful data from big omics data in analysis
- Data Integration
- Single omics vs multiomics

Moderator:
HARPREET SAINI, Senior Director of Bioinformatics, **Astex Therapeutics**

Panellists:
ARMAN RAHMAN, Assistant Professor of Anatomy, **University College Dublin**

WOUTER DE JONGE, Professor of Neurogastroenterology, **Amsterdam UMC**

EDINA SILAJDZIC, Lecturer, **King's College London**

INTERACTIVE

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONF ROOM 5: **GIELGUD & BURTON** - SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Statistical Analysis Of Spatial Patterns In Tumour Images

We present Spatiopath, a method to analyse spatial patterns within the tumour microenvironment that extends Ripley's K function to characterise cell-cell and cell-tumour interactions. We apply it to images of lung tumour sections, revealing significant spatial patterns such as mast cells accumulating near T cells and the tumour epithelium. Spatiopath enables a better understanding of immune responses and may help identify biomarkers.

JEAN-CHRISTOPHE OLIVO-MARIN, Professor & Head of the Quantitative Image Analysis Unit, **Institut Pasteur**

Light Mediated Discovery Of Surfaceome Nanoscale Organisation

- LUX-MS Technology: Maps protein interactions on living cells using lightcontrolled tools
- Theragnostic Potential: Advances drug targeting by decoding extracellular signalling
- Precision Medicine: Integrates with Swiss/ETH projects to enhance clinical decisions

BERND WOLLSCHEID, Head of Institute for Translational Medicine, Professor & Group Head, **ETH Zurich**

CONF ROOM 6: **OLIVIER** - SPATIAL BIOLOGY IN PHARMA & TRANSLATIONAL DRUG RESEARCH

Panel Discussion:
Utilising Spatial Biology In Pharma R&D

- Enhancing precision medicine in drug research
- Bridging research to clinical applications
- Facilitating Academia & Industry collaboration

Panellists:
BERND WOLLSCHEID, Head of Institute for Translational Medicine, Professor & Group Head, **ETH Zurich**

NANA AKUMANYI, Spatial Regional Account Manager, **Bruker Spatial Biology**

VIRGINIA SAVOVA, Senior Director of Cell-Targeted Precision Medicine, **AstraZeneca**

INTERACTIVE

Multiplex Immunofluorescence: The Next Revolution In Molecular Pathology?

Multiplex immunofluorescence has the potential to reshape molecular pathology by enabling high-resolution spatial analysis of the tumour microenvironment. My talk will explore its potential to enhance diagnostics, and accelerate translational research, using the example of application to clinical PD-L1 reflex testing. Drawing on experience across national molecular programmes and digital pathology innovation, I will reflect on key challenges and opportunities in advancing this powerful technology at scale.

MATTHEW HUMPHRIES, Director of Research Operations, **Leeds Teaching Hospitals NHS Trust**

DIGITAL PATHOLOGY & AI

CONF ROOM 7: **RUTHERFORD** - DIGITAL PATHOLOGY IMPLEMENTATION - IMAGE ANALYSIS & AI

How To Go Digital? Practical Tips And Considerations

RAHUL DEB, Consultant Histopathologist, Lead Breast Pathologist, **University Hospitals of Derby & Burton**

Q&A session & transition time between conference rooms

Update On Cellular Pathology AI Deployment Experience In Wales

An overview of the recent developments and experiences in deploying AI technologies across Wales in cellular pathology. It covers case studies, key challenges, and measurable outcomes, with a focus on digital pathology and AI integration in clinical setting. The talk aims to highlight both technical progress and the diagnostic impacts of AI deployment in the region.

MUHAMMAD ASLAM, Consultant Pathologist, National Clinical Lead for Digital Pathology and AI, Wales, **Betsi Cadwaladr University Health Board**

Day One | 30 September 2025

BIOMARKERS & PRECISION MEDICINE

CONF ROOM 1: WESTMINSTER - BIOMARKER IDENTIFICATION, VALIDATION, IN ONCOLOGY, IO & IMMUNOLOGY

Track Chair: Folake Orafidiya, Senior Scientist, **Avacta**

13:05

Conference Room 1 - Panel Discussion: Building The Next Era Of Precision Medicine: Stakeholder Collaboration Across Biomarkers, Diagnostics, Omics & Therapeutic Innovation

Moderator:
MIKE MESSENGER, Head of Regulatory Strategy, **BIVDA**

Panellists:
SENIOR REPRESENTATIVE, **Labcorp**
MARISCA MARIAN, Oncology Market Access Strategy Leader, **Bayer**
ALEXANDRA SEVKO, VP of Translational Science, **Amphista Therapeutics**
KIRI GRANGER, Chief Scientific Officer, **Monument Therapeutics**

INTERACTIVE

13:35 **LUNCH BREAK:** Poster Displays & 1-2-1 Meetings x3

14:35

Solution Provider Presentation

Quanterix
Discovery Fueled by Ultra-Sensitivity

Senior Representative, **Quanterix**

CONF ROOM 2: ST JAMES - DIAGNOSTIC BIOMARKERS & REGULATIONS

Track Chair: ALAIN VAN GOOL, Professor of Personalised Healthcare, **Radboud University Medical Centre**

Start-Up Zone Pitches

10-Minute Presentation: **UltraBright Biotech**

10-Minute Presentation: **EndoGene.bio**

endogene.bio

CONF ROOM 3: MOORE - BIOMARKERS FOR CLINICAL DEVELOPMENT

Track Chair: Emily Adams, Associate Professor, **University of Oxford**

Conference Room 2 - Panel Discussion: The Future Of Precision Medicine And Benefits For The Patient

Moderator:
LAURENT AUDOLY, Cheif Executive Officer & Co-Founder, **PriveBio, Inc**

Panellists:
JOHAN LUTHMAN, Executive Vice President and Head of R&D, **Lundbeck**
MIRO VENTURI, Operating Partner, **ARCHIMED**
MO JAIN, Founder & Chief Scientific Officer, **Sapient**
BELINDA NEDJAI, Associate Professor & Director of Molecular Epidemiology Laboratory, **Queen Mary University of London**

INTERACTIVE

Designing For Success: Navigating Early-Phase Translational Medicine Studies

ARC

Practical insights and real-world case studies from ARC's collaborations with pharmaceutical and diagnostic teams on early-phase translational and precision medicine trials.

BETHANY MONTGOMERY, Technology Specialist, **ARC Regulatory**

CONF ROOM 4: ABBEY - GENOMIC & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT

Track Chair: Harpreet Saini, Senior Director Bioinformatics, **Astex Therapeutics**

Proteomics To Advance Precision Medicine

seer

Application of different omic technologies is now feasible at population scale. This talk will present examples of how the integration of proteomics in large patient and population studies can help to predict disease risk, understand mechanisms, and reveal shared connections between rare and common diseases. Studies include different proteomic technologies and an investigation how these can be combined and how their complementarity can be employed for synergistic insights into human health.

CLAUDIA LANGENBERG, Director, **Seer**

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONF ROOM 5: GIELGUD & BURTON - SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Track Chair: TBA

Conference Room 5 - Panel Discussion: Addressing The Future Needs Of Spatial Multi-Omics

- Future of spatial biology
- Moving towards the practical implementation of spatial findings
- How to translate into precision medicine

Panellists:
AZAM HAMIDINEKOO, Associate Director, Clinical Pharmacology & Safety Sciences, **AstraZeneca**
FAN LIU, Professor & Group Head, **FMP Berlin**
INÊS SEQUEIRA, Associate Professor, Group Leader, Spatial Biology Hub, **Queen Mary University London**
AMONIDA ZADISSA, Associate Director of Informatics, **UK Dementia Research Institute**
NIK MATTHEWS, Head of Imperial BRC Genomics Facility, **Imperial College London**
Senior Representative, **Ariadne.ai**

INTERACTIVE

Single-Cell Identity And Heterogeneity In Its Environment: Where Innovations Push The Understanding Of Spatial Biology

Leica MICROSYSTEMS

PRZEMEK FLESZAR, Advanced Workflow Specialist, **Leica Microsytems**

CONF ROOM 6: OLIVIER - SPATIAL BIOLOGY IN PHARMA & TRANSLATIONAL DRUG RESEARCH

Track Chair: Stephanie Traub, Associate Director, BSM & Biomarker Lead, **UCB**

Spatial Proteomic Characterisation Of Renal Cell Carcinomas Identifies Metabolic Reprogramming Of The TME Associated With Disease Progression

NEO GENOMICS

Spatial proteomics provides valuable insights into cell characterisation within the tumour microenvironment. Using our Paletrra™ AI-driven solution, we explored the relationship between the immunogenic profile of clear cell renal cell carcinoma (ccRCC) and metabolic reprogramming. This end-to-end platform generates whole-tissue data with enhanced histological context, enabling unbiased spatial analysis to advance understanding and therapeutic development.

Senior Representative, **Neo Genomics**

DIGITAL PATHOLOGY & AI

CONF ROOM 7: RUTHERFORD - DIGITAL PATHOLOGY IMPLEMENTATION - IMAGE ANALYSIS & AI

Track Chair: TBA

Conference Room 7 - Panel Discussion: Building A Business Case For Digital Pathology

- Wants and needs from different stakeholders
- ROI
- Clinical benefits
- Efficiency & quality gains

Moderator:
DAVID SNEAD, Professor & Consultant Pathologist **UHCW NHS Trust Coventry and Director of PathLAKE**

Panellists:
HUW BANNISTER, Senior Director of Global Diagnostics & Digital and Computational Pathology, **AstraZeneca**
MATTHEW HUMPHRIES, Director of Research Operations, **Leeds Teaching Hospitals NHS Trust**
PAUL J VAN DIEST, Professor and Head, Department of Pathology, **University Medical Center Utrecht**
SONALI NATU, Consultant Cellular Pathologist, **and Clinical Lead for Pathology, Northeast and North Cumbria, Tees Valley Pathology Services**
VANDANA MALLEMPATI, Senior Director of Product Management, **Iron Mountain**

INTERACTIVE

Silver Level Solution Provider Presentation

Attendees Are Welcome To Attend Co-Located Sessions

Day One | 30 September 2025

BIOMARKERS & PRECISION MEDICINE

CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION, VALIDATION, IN ONCOLOGY, IO & IMMUNOLOGY

Why Genomic Profiling Is Important For Patients' Survival And Outcomes?

JO TAYLOR BEM, Founder, **After Breast Cancer Diagnosis & METUPUK**

CONF ROOM 2: **ST JAMES** - DIAGNOSTIC BIOMARKERS & REGULATIONS

Navigating Complexity Of Biomarker Subgroups To Accelerate Drug Approval

The precision medicine strategy gets complex for oncology studies involving multiple biomarker subgroups and diagnostics tests. For these trials, regulators expect robust evaluation of efficacy in each biomarker subgroups enrolled in the trial before deciding the final drug approval label. These perspectives will be discussed as well as to how effective biomarker/ diagnostic testing strategies can minimise delays to drug approval.

NITIN JAIN, Director of Franchise Project Management, **AstraZeneca**

CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL DEVELOPMENT

Translating Cancer Research Into Novel Therapies

- Biomarker strategies for the identification of the right patients for targeted therapy
- Biomarkers for monitoring drug response
- Translational analysis of mechanisms of resistance to guide future combination strategies

ELIZABETH HARRINGTON, Global Head of Translational, Medicine &Targeted Therapy Franchise, **AstraZeneca**

CONF ROOM 4: **ABBEY** - GENOMIC & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT

Predicting Therapeutic Response Using Genomics In Inflammatory Diseases And Beyond

Many patients with inflammatory diseases do not respond to individual therapies. Genomics plays a role in this process. We have used a Bayesian approach to analyse common variants in an ulcerative colitis cohort to identify a genomic signature that can predict response to anti-integrin therapy. This will be developed for use in clinical trial design and/or treatment selection.

NEIL HUMPHREYS-KIRILOV, Associate Director of Human Genomics, **C4X Discovery**

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONF ROOM 5: **GIELGUD & BURTON** - SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Revealing Spatial Interactome Of The Cell By Cross-Linking Mass Spectrometry

The specific functions of cellular organelles and sub-compartments depend on their protein content, which can be characterised by spatial proteomics approaches. Here, we develop a cross-linking assisted spatial proteomics (CLASP) to map sub-organelle proteomes and membrane protein topology and revealed spatial interactomes of organelles such as the mitochondria and even the whole cell.

FAN LIU, Professor & Group Head, **FMP Berlin**

CONF ROOM 6: **OLIVIER** - SPATIAL BIOLOGY IN PHARMA & TRANSLATIONAL DRUG RESEARCH

IMMUcan: Large-Scale Spatial IO Profiling For Biomarker And Target Discovery

- IMMUcan is an EU-funded public-private consortium profiling the TME of >2,500 cancer patients
- The novelty is to combine molecular and spatial cellular readouts at large scale
- Use cases for biomarker and drug target discovery will be discussed

HENOCH HONG, Associate Director, **Merck KGaA**

DIGITAL PATHOLOGY & AI

CONF ROOM 7: **RUTHERFORD** - DIGITAL PATHOLOGY IMPLEMENTATION - IMAGE ANALYSIS & AI

The NPIC AI FORGE: A Unique Multi-Scanner Facility For Data Acquisition For Digital Pathology Artificial Intelligence

The development and use of AI within digital pathology is becoming more common and offers a myriad of potential uses. Despite the promise of AI, it is not without limitations. My talk will discuss our novel multi-scanner facility, which can support the creation of richer datasets through the replication of pathology slides across multiple scanners from different vendors, supporting the creation of more generalisable AI.

DANNY KAYE, Lead Digital Pathology Scientist, **Leeds Teaching Hospitals NHS Trust, NPIC**

Q&A session & transition time between conference rooms

15:25

From Plasma To Placenta: Translational Proteomic Signatures Across Diverse Clinical Matrices

Synexa Life Sciences applies Olink® PEA to diverse matrices, enabling multiplex proteomic analysis across disease areas. We identified neuroinflammatory markers in PTSD serum, phenotype-specific differences in HIV plasma and CSF, and immune dysregulation in placental tissue. These studies showcase Olink's sensitivity and highlight sample selection's critical role in translational biomarker research.

ANDREIA SOARES, Head of Scientific Strategies, **Synexa Life Sciences**

Solution Provider Presentation

Senior Representative, **Surfix Diagnostics**

Comprehensive Genomic Profiling To Support Global Oncology Clinical Trials

Illustrating IQVIA Laboratories' approach to supporting our sponsor's global oncology clinical trials, including regional considerations - such as IVDR in Europe - and assay validation and verification approaches, with a focus on Illumina's TruSight Oncology 500 tissue and ctDNA assay portfolio of next-generation sequencing assays for mutation profiling.

DAVID LATTO, Director Biomarker Liason, **Rules Based Medicine**

Practical Implementation of Clinical Standards and IVDR Compliance in Multi-Omic Data Generation

Genseq, an ISO15189, CAP/ CLIA clinical diagnostics company, delivers multi-omic genomics solutions for clinics and biopharma. This talk explores applying clinical, regulatory, and sustainability standards to genomics workflows, covering validation of single-cell/nuclei workflows in NASH/NAFL tissue, ISO15189 companion diagnostic services, and IVDR-compliant whole exome sequencing development.

Senior Representative, **GenSeq**

MACSima™: The Complete Toolbox For Spatial Biology

The emergence of spatial biology heralds a paradigm shift in our understanding of biological systems, revealing previously unseen layers of complexity. Here, we will discuss how MACSima is driving advancements in disease therapies and unraveling the complexity of the tumor microenvironment.

LILIA DRAGANOVA, PhD, Instrument Sales Specialist - UK North & Ireland,**Miltenyi Biotec**

Creative Solutions To Scientific And Technical Challenges In Digital Pathology

Dr Marta Czapranska Senior Scientist, **Concept Life Sciences**

Silver Level Solution Provider

Attendees Are Welcome To Attend Co-Located Sessions

Q&A session & transition time between conference rooms

Day One | 30 September 2025

BIOMARKERS & PRECISION MEDICINE

CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION, VALIDATION, IN ONCOLOGY, IO & IMMUNOLOGY

15:50

Use Of Mass-Spec Based Proteomics For Biomarker Discovery In Clinical Plasma And Tissue Samples

BIOGNOSYS
NEXT GENERATION PROTEOMICS

DANIEL REDFERN, Senior Director of Business Development, **Biognosys AG**

CONF ROOM 2: **ST JAMES** - DIAGNOSTIC BIOMARKERS & REGULATIONS

Precision Medicine Beyond Oncology: Unlocking the Next Frontier in Biomarker-Driven Therapies

FOUNDATION MEDICINE®

Precision medicine has significantly impacted cancer drug development and treatment. This talk will review how lessons from the oncology field are now being applied to other therapeutic areas, including cardiometabolic and neurodegenerative diseases.

DAVID FABRIZIO, VP, Commercial Strategy and Medical Innovation, **Foundation Medicine**

CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL DEVELOPMENT

Development Of A Novel AI-Based Alzheimer's Diagnostic. From Assay Concept To Clinical Validation And Regulatory Submission

CellCarta

TODD CHERMAK, SVP & Global Business Head Immunology & Proteomics, **Cellcarta**

CONF ROOM 4: **ABBEY** - GENOMIC & MULTI-OMIC APPROACHES IN BIOMARKER DISCOVERY & DEVELOPMENT

Automating Sample Prep: Next-Generation Workflows for Biomarker Discovery

opentrons

- How automation streamlines reproducible LC–MS sample prep for proteomics and genomics
- New technologies to enable fully automated workflows
- Increase throughput without increasing footprint

DANIEL LORD, Sales Director, **Opentrons**

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONF ROOM 5: **GIELGUD & BURTON** - SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES

Accelerating Spatial Proteomics: Innovations In Spectral Multiplex Fluorescence Imaging With The Invitrogen™ EVOS™ S1000 System

ThermoFisher SCIENTIFIC

Genseq is an ISO15189, CAP/CLIA clinical diagnostics company providing clinics and biopharma partners with multi-omic genomics solutions. The talk will summarise the experience of applying multiple clinical, regulatory and sustainability standards to genomics data generation workflows including validation of single cell/nuclei workflows in NASH/NAFL tissue, parallel development of ISO15189 companion diagnostic services for treatments and IVDR compliance to whole exome sequencing.

ADYARY FALLARERO, Senior Product Manager, **Thermo Fisher**

CONF ROOM 6: **OLIVIER** - SPATIAL BIOLOGY IN PHARMA & TRANSLATIONAL DRUG RESEARCH

Spatial Biology At Scale With Orion Technology

RARECYTE

Orion revolutionises spatial biology with high-throughput, single-round imaging, eliminating iterative cycling and enhancing image quality. Delivering 18 plex in a single scan, Orion streamlines workflows and accelerates discovery. It enables comprehensive microenvironment profiling, uncovering disease mechanisms and advancing prognostic and predictive biomarker discovery. Case studies showcase its transformative applications.

MICKAEL MEYRAND, Field Application Scientist, **Rarecyte**

DIGITAL PATHOLOGY & AI

CONF ROOM 7: **RUTHERFORD** - DIGITAL PATHOLOGY IMPLEMENTATION - IMAGE ANALYSIS & AI

Bronze Level Solution Provider

Attendees Are Welcome To Attend Co-Located Sessions

16:15

AFTERNOON NETWORKING BREAK & REFRESHMENTS:

Poster Displays & 1-2-1 Meetings x3

17:15

Preclinical Strategies To Define Immuno-Oncology Biomarkers For Clinical Translation

Immuno-oncology agents are often combined with standard-of-care therapies or other immunomodulatory molecules, presenting challenges in tracking biomarkers intrinsically associated with the contribution of specific components. To address these challenges and enhance the effectiveness of clinical development programmes, rational experimentation using suitable preclinical models is invaluable. This presentation will outline strategies employed by the Clinical Immuno-Oncology Discovery team at AstraZeneca.

JIM EYLES, Director of Clinical Immuno-Oncology Discovery Group, **AstraZeneca**

Navigating The Path: Considerations For Clinical Trials Involving Lab Developed Tests

The In Vitro Diagnostic Regulation and the FDA LDT Rule represent a significant paradigm shift in requirements related to the use of biomarker tests in pharmaceutical clinical trials. Clinical trial sponsors need to understand and proactively address changes while navigating the complexities to ensure that the data generated through the trial is compliant with the regulations and can support subsequent regulatory submissions. This session is geared towards identifying specific challenges and potential solutions.

VIHANGA PAHALAWATTA, Director of Regulatory Affairs & Companion Diagnostics, **Abbvie**

ICT01, First-In-Class Anti-BTN3A mAb Selectively Activating γ9δ2 T Cells: Translational Results From Phase I And Dose Selection

ICT01 is an anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, triggering a downstream immunological cascade through secretion of pro-inflammatory cytokines, and further augmenting the anti-tumour immune response. Favourable safety profile together with promising efficacy signals is observed in multiple haematological and solid tumour patients, and the 10 mg ICT01 dose is selected as RPD2 based on PK/PD modelling.

EMMANUEL VALENTIN, Vice President of Translational Medicine, **ImCheck Therapeutics**

Omics Technologies And Computational Approaches In Drug Discovery

Discovering and developing new drugs is a time-consuming and expensive process. Use of genome-wide, high-throughput omics technologies and computational approaches for integrating multi-dimensional data in drug discovery can lead to more informed drug target selection, biomarker identification and accelerated drug development. In my talk, I will present examples of how multi-omics data integration approaches can be used for identifying biomarkers for patient stratification in pre-clinical and clinical settings.

HARPREET SAINI, Senior Director of Bioinformatics, **Astex Therapeutics**

Uncovering Scarless Healing: A Multiomics Atlas Of Oral & Skin Fibroblast Heterogeneity

Oral mucosa heals with minimal scarring, unlike skin, but its cellular diversity remains poorly understood. Using single-cell and spatial omics, we mapped fibroblast heterogeneity across human and mouse oral tissues and skin, revealing key regenerative populations. Our multimodal atlases uncover molecular mechanisms of scar-free healing and offer a valuable resource for advancing tissue repair research.

INÊS SEQUEIRA, Associate Professor, Group Leader, Spatial Biology Hub Lead, **Queen Mary University London**

Translation In The Clinic

DEBAYAN MUKHERJEE, Principal Scientist of Spatial Multiplex Imaging, In Vitro/ In Vivo Translation Research, Pharma R&D, **GSK**

Digital Pathology Multimodal Analysis And Complex Biomarkers In Oncology

There is a mismatch between the complexity of the biology targeted by new drugs and the simplicity of the predictive biomarkers in use; this is why DNA damage response or immuno-oncology related drugs have a small repertoire of predictive biomarkers. In this lecture, we will explore ways to create a new generation of complex biomarkers applicable in the routine setting.

MANUEL SALTO-TELLEZ, Professor of Integrative Pathology & Director of the RMH/ICR Integrative Pathology Unit, **Institute of Cancer Research**

17:40

NETWORKING DRINKS & END OF DAY ONE

Day Two | October 01, 2025

07:40 **Badge Collection**

BREAKFAST ROUNDTABLES

Biomarkers
Improving Support For Industry–Academic Collaboration

This session will explore how industry-academic collaboration can accelerate digital pathology and biomarker discovery for cancer. We will specifically discuss how smaller industry partners can leverage academic settings as their R&D engine, utilising AI-driven and multiomics platforms to bridge the gap between research and clinical application. The goal is to personalise cancer treatment and advance the future of precision medicine.

Moderator: ARMAN RAHMAN, Assistant Professor, **University College Dublin**

Biomarkers
Introducing AI-Derived Digital Biomarkers For Clinical Trials And Patient Monitoring

Moderator: RICHARD FESTENSTEIN, Clinical Professor of Molecular Medicine, Department of Brain Sciences, **Imperial College London**

Biomarkers
Assessing Clinical Trials For Global IVD Regulatory And Quality Compliance

Biomarkers play a pivotal role in evaluating clinical trials, offering measurable indicators of safety, efficacy, and compliance. Their integration is essential for meeting global in vitro diagnostic (IVD) regulatory standards and ensuring quality assurance. Standardised biomarker validation supports harmonisation across jurisdictions, strengthens trial credibility, and accelerates translation of innovations into practice, ultimately improving patient outcomes and regulatory confidence worldwide.

Moderator: MARIYA IVANOVSKA, Chief Assistant Professor, **The Medical University of Plovdiv**

Spatial Biology
FAIR Data Practices And Project Design For Spatial Profiling Techniques

Interactive discussion about un-resolved issues regarding FAIR spatial data.

Topics (among others):
- Open questions / issues regarding metadata management
- Data management plan: sample - experimental setup - data acquisition
- Repositories for sharing data & data linking
- Questionnaire: share your challenges

Key results will be shared at the end of the conference by Amonida Zadissa (see programme).

Moderator: JAN-PHILIPP MALLM, Head of Single Cell Open Lab **DKFZ, German Cancer Research Center** & AMONIDA ZADISSA, Associate Director of Informatics, **UK Dementia Research Institute**

Digital Pathology & AI
Imaging Based Standardisation In Digital Pathology: A Necessary Step Or A Barrier To Innovation?

Imaging based standardisation in digital pathology promises interoperability, safety and AI readiness enabling cross-site reporting and consistent quality. Strict standards may limit vendor innovation, would be associated with un-necessary transition costs and risk lowest common denominator solutions. Balancing harmonisation and flexibility is crucial. The roundtable is a discussion on how to balance harmonisation with flexibility so that it can be an enabler of progress and not be a barrier if applied to rigidly.

Moderator: SONALI NATU, Consultant Cellular Pathologist, **Tees Valley Pathology Services and Clinical Lead for Pathology, Northeast and North Cumbria**

Digital Pathology & AI
Real World Learning From Deploying Digital And Computational Pathology At Scale

Moderator: HUW BANNISTER, Senior Director of Global Diagnostics, Digital and Computational Pathology, **AstraZeneca**

08:05

08:40 **Conference Room 1: Fireside Chat with Professor Sir Mark Caufield**

PROFESSOR SIR MARK CAULFIELD, Vice Principal for Health, Queen Mary's Faculty of Medicine and Dentistry; Director of the NIHR Barts Biomedical Research Centre; President, **British Pharmacological Society**

Moderator: MIRO VENTURI, Operating Partner, **ARCHIMED**

Q&A session & transition time between conference rooms

Day Two | October 01, 2025

	BIOMARKERS & PRECISION MEDICINE				SPATIAL BIOLOGY FOR PRECISION MEDICINE	DIGITAL PATHOLOGY & AI
	CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION & VALIDATION: NEUROSCIENCE & CO-MORBIDITY	CONF ROOM 2: **ST JAMES** - NEW & EMERGING BIOMARKER TECHNOLOGIES FOR ANALYSIS	CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL TRIALS	CONF ROOM 4: **ABBEY** - BIOMARKERS FOR DIAGNOSTICS & PRECISION MEDICINE	CONF ROOM 5: **GIELGUD & BURTON** - AI IMAGE ANALYSIS & DATA ANALYTICS IN SPATIAL BIOLOGY	CONF ROOM 6: **OLIVIER** - COMPUTATIONAL PATHOLOGY & UTILISING DIGITAL PATHOLOGY IN PHARMA RESEARCH
	Track Chair: Giovanna Lalli, Director of Strategy & Operations, **Life Arc**	*Track Chair:* James Schofield, Founder & Chief Executive Officer, **TopMD Precision Medicine**	*Track Chair:* Paul Rhyne, Senior Director, Scientific Solutions, **Luminex**	*Track Chair:* Valerie Taly, CNRS Research Director & Group Leader, **University of Paris Descartes**	*Track Chair:* Priya Narayanan, Senior Scientific Officer, **Institute of Cancer Research**	*Track Chair:* Vandana Mallempati, Senior Director of Product Management, **Iron Mountain**
09:10	**Track Keynote:** **Precision Medicine In Neuroscience: The Role Of Digital Biomarkers** Neuroscience drug development has historically suffered a low success rate, in part due to a lack of diagnostic specificity. We are entering a new era of precision medicine in psychiatry and neurology, enabled by novel digital biomarkers. Monument Tx is a clinical-stage biotech company developing stratified therapeutics for schizophrenia and neuroinflammation, exemplifying this approach. KIRI GRANGER, Chief Scientific Officer, **Monument Therapeutics**	**Track Keynote:** **Proteomics-Based Predictive Biomarkers For Immunotherapy Response** Immune checkpoint inhibitors show limited response in Head and Neck cancer. We developed a proteomics-based classification system, analysing 128 patients' FFPE samples with 11,000+ proteins per sample. Machine learning-based classification achieved 86% sensitivity, 90% PPV. Identified resistance mechanisms offer insights for personalised immunotherapy strategies in HNSCC. OLGA NISSAN, CEO, **Protica Bio**	**Track Keynote:** **Patient Selection Approaches in AstraZeneca** Precision Medicine is central to AstraZeneca's scientific endeavours. By deepening our understanding of response biology and advancing diagnostic innovation, we tailor treatments to individuals for optimal outcomes. This presentation showcases our groundbreaking approaches to delivering the right treatments to patients. MARIA ORR, Head of Precision Medicine Biosamples & Early Oncology, **AstraZeneca**	**Track Keynote:** **Multimodal Diagnostics For Precision Oncology: An Industry Perspective** Precision oncology has evolved rapidly, with over 65% of solid cancer approvals targeting specific genomic alterations. Industry, associations, and clinicians need to work together to see the full potential of diagnostics. Combining IHC, NGS, ctDNA, and digital pathology will define the new era of multimodal diagnostics. ESPEN WALKER, Global Head of Medical Diagnostics, **AstraZeneca**	**Track Keynote:** **Advancing Biomarker Discovery Through AI-Driven Spatial Biology: A Comprehensive Pipeline Approach** Spatial Biology, powered by AI, is advancing biomarker discovery and therapeutic innovation. We developed and utilised an agile pipeline to translate and unlock the information in spatial imaging techniques and decipher cell interactions to inform treatment dynamics. By integrating spatial data with AI-driven analysis, in our use case, the results demonstrated enhanced understanding of cellular dynamics, supporting biomarker identification and enabling personalised treatment strategies along with tailored therapeutic approaches. AZAM HAMIDINEKOO, Associate Director of Clinical Pharmacology & Safety Sciences, **AstraZeneca**	**Track Keynote:** **Next-Gen AI-Based Breast Cancer Grading For Improved Therapy Selection** We studied the use of deep learning to assess a range of breast-cancer related tissue features: presence of lymph node metastases, extent of lymphatic infiltrate within tumours, and the components of tumour grading. It was shown that DL enables reproducible, quantitative tumour feature extraction, showing a good correlation with pathologists' scores and with patient outcome. Our current research involves larger-scale validation with pathologists to study the added value of the developed algorithms in terms of efficiency and diagnostic accuracy. AI-based biomarkers to select the optimal treatment for individual patients were also studied. JEROEN VAN DER LAAK, Professor of Computational Pathology, **Radboud University**
	Q&A session & transition time between conference rooms					
09:35	**Diamond/Platinum Level Solution Provider Presentation** *Attendees Are Welcome To Attend Co-Located Sessions*	**Diamond/Platinum Level Solution Provider Presentation** *Attendees Are Welcome To Attend Co-Located Sessions*	**Multiplex Luminex Assay Development For Malaria Vaccine Immunology** Luminex SAMUEL PROVSTGAARD-MORYS, PHD Student/ Research Assistant, **Luminex**	**Diamond/Platinum Level Solution Provider Presentation** *Attendees Are Welcome To Attend Co-Located Sessions*	**Solution Provider Presentation** Navinci CRESCENS TIU, Clinical Scientist, **Navinci**	**Diamond/Platinum Level Solution Provider Presentation** *Attendees Are Welcome To Attend Co-Located Sessions*
10:00	**MORNING NETWORKING BREAK & REFRESHMENTS:** Poster Displays & 1-2-1 Meetings x4					

Day Two | October 01, 2025

	BIOMARKERS & PRECISION MEDICINE				SPATIAL BIOLOGY FOR PRECISION MEDICINE	DIGITAL PATHOLOGY & AI
	CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION & VALIDATION: NEUROSCIENCE & CO-MORBIDITY	CONF ROOM 2: **ST JAMES** - NEW & EMERGING BIOMARKER TECHNOLOGIES FOR ANALYSIS	CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL TRIALS	CONF ROOM 4: **ABBEY** - BIOMARKERS FOR DIAGNOSTICS & PRECISION MEDICINE	CONF ROOM 5: **GIELGUD & BURTON** - AI IMAGE ANALYSIS & DATA ANALYTICS IN SPATIAL BIOLOGY	CONF ROOM 6: **OLIVIER** - COMPUTATIONAL PATHOLOGY & UTILISING DIGITAL PATHOLOGY IN PHARMA RESEARCH
11:20	**Gold Level Solution Provider Presentation** *Attendees Are Welcome To Attend Co-Located Sessions*	**Solution Provider Presentation** Olink Senior Representative, **Olink**	**Challenges And Solutions In Receptor Occupancy Assay Development - Flow Cytometry** PRECISION for medicine Receptor occupancy (RO) assays are essential tools to assess drug-target engagement but are influenced by biological and technical variables. Changes in receptor expression, cell population dynamics, drug effects, and sample handling, among others can all skew RO calculations. Careful optimisation and validation are essential to ensure reliable results and avoid delays in clinical development. CIRO NOVAES, Principal Scientist, Cell Biology, **Precision For Medicine**	**Planning For Success When Developing & Validating Assays For Global Clinical Trials** ALMAC • Key considerations for the development and analytical validation of assays for clinical stratification • Implementation of clinical trial assays across global jurisdictions (EU, US and China) • Quality control, surveillance of assay performance and clinical trial monitoring CHERYL MCFARLANE, Associate Director, Assay Development & Validation, **Almac Diagnostic Services**	**Mapping Biology In High Definition: Spatial Multiomics For Biomarker Discovery & Translational Breakthrough** BRUKER Join our presentation as we explore the future of multiomics research with Bruker Spatial Biology. Discover our fit for purpose solutions, integrating spatial transcriptomics, proteomics, genomics and bulk multiomics to unlock new biological insights. JOANA CAMPOS, Senior Study Manager, **ProPath UK** RICHARD BUUS, Senior Field Applications Scientist, **Bruker Spatial Biology**	**Navigating Pathology In Translational Research & Clinical Trials** DIAGNEXIA ANALYTIX Diagnexia Analytix acts as a lighthouse in translational research and clinical trials, guiding sponsors through storms of unclear endpoints, CRO variability, and limited pathology expertise. By embedding expert pathology leadership into workflows, we bring clarity, consistency, and regulator-ready data. This session highlights a case study showing how expert pathology support illuminates the path to trial success. GEORGIA CRESWELL, Pathology Solutions Specialist, **Diagnexia Analytix**
	Q&A session & transition time between conference rooms					
11:45	**Improving Early Detection Of Dementia By Multimodal Biomarker Integration** Dementia is one of the biggest global health challenges. Emerging blood and digital biomarkers are opening novel, potentially transformative avenues for early detection of disease risk as well as early diagnosis. With Alzheimer's disease as the trailblazer, this talk will also discuss challenges and opportunities for multimodal data integration in promoting more accurate diagnosis across different dementia subtypes. GIOVANNA LALLI, Director of Strategy & Operations, **Life Arc**	**Blood And Spatial Tumour Proteomics Inform The Future Precision Prevention Of Prostate Cancer** In EPIC's study (620 matched pairs), 5,420 plasma proteins were measured; meta-analysis with two other prospective studies (totalling 3,198 prostate cancer cases) identified significant associations: ACP3, CNTNAP2, GP2, TSPAN1, KLK15 (positive) and FLT3LG (inverse). Further spatial tumour profiling shows differing gene and protein expression by clonal lineage. These findings reveal novel mechanisms with potential for early detection. KARL SMITH-BYRNE, Senior Molecular Epidemiologist, **Cancer Epidemiology Unit (CEU), University of Oxford**	**End-To-End Automation: Moving Flow Cytometry Into The Digital Age** We developed six harmonised spectral flow cytometry panels with shared backbones, standardised markers, and gating strategies to streamline reporting and enable integration with CDISC's Cell Phenotyping domain. Through modular automation spanning sample processing to analysis, we reduce manual steps and enhance efficiency, consistency, and scalability in our regulated GCP lab. IRENE DEL MOLINO DEL BARRIO, Principal Scientist, **GSK**	**Methylation Based Biomarkers For Cancer Patient Follow-Up** Liquid biopsy approaches offers great advantages for cancer patient follow-up. Among the several cancer specific components that can be tracked in liquid biopsy, circulating tumor DNA (ctDNA) is especially suited to fine tracking of cancer evolution. This presentation will focus on the combined use of cancer specific methylation markers and digital PCR for ctDNA quantitative detection in several cancers. VALERIE TALY, CNRS Research Director & Group Leader, **University of Paris Descartes**	**Beyond IHC - The Added Value Of Morphometrics In Biomarker Analysis & Precision Medicine** How IHC is being used clinically as a biomarker in precision medicine? How spatial transcriptomics and multiplex IHC can provide context to biomarker results? Added value of digital pathology and artificial intelligence models to reflect underlying biology in refined morphometric analysis STEPHANIE CRAIG, Lecturer in Precision Medicine, **Queen's University Belfast**	**Emerging Roles For Large Language Models And Agentic AI In Cellular Pathology** Examines the emerging use of large language models and Agentic AI systems in cellular pathology. The ability of these systems to present data from multiple different sources in a succinct meaningful way is relevant to cellular pathology in both research and diagnostic work-up of clinical cases. Other applications are emerging in quality management systems where important efficiencies can be realised, particularly in laboratories grappling with short staffing. DAVID SNEAD, Professor & Consultant Pathologist, **UHCW NHS Trust Coventry and Director of PathLAKE**
	Q&A session & transition time between conference rooms					

Day Two | October 01, 2025

	BIOMARKERS & PRECISION MEDICINE				SPATIAL BIOLOGY FOR PRECISION MEDICINE	DIGITAL PATHOLOGY & AI
	CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION & VALIDATION: NEUROSCIENCE & CO-MORBIDITY	CONF ROOM 2: **ST JAMES** - NEW & EMERGING BIOMARKER TECHNOLOGIES FOR ANALYSIS	CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL TRIALS	CONF ROOM 4: **ABBEY** - BIOMARKERS FOR DIAGNOSTICS & PRECISION MEDICINE	CONF ROOM 5: **GIELGUD & BURTON** - AI IMAGE ANALYSIS & DATA ANALYTICS IN SPATIAL BIOLOGY	CONF ROOM 6: **OLIVIER** - COMPUTATIONAL PATHOLOGY & UTILISING DIGITAL PATHOLOGY IN PHARMA RESEARCH
12:10	**From Biospecimen To Breakthrough: Powering Precision Biomarker Discovery With Disease-State Insights** BIOIVT ELEVATING SCIENCE This presentation highlights how purpose-built, regulatory-grade biospecimens are essential for reliable biomarker discovery, validation, and translation. Discover how these high-quality, disease-state samples power precision medicine programs, from initial research insights to achieving significant clinical impact and regulatory approval across every phase. BRAD EVANS, Senior Scientific Advisor for Disease State, Scientific Affairs, **BioIVT**	**Solution Provider Presentation** HOLOGIC Diagenode Senior Representative, **Hologic Diagenode**	**Dynamic Monitoring And Biomarker Discovery: ctDNA-Driven Insights Across The Cancer Continuum** Burning Rock Dx Discover how Burning Rock supports clinical and exploratory studies with ctDNA-based genomic and methylation assays, offering biomarker insights and dynamic monitoring strategies tailored to global and regional oncology development programmes. MICHAEL CHEN, Senior Translational Medicine Scientist, **Burning Rock DX**	**Beyond Symptoms: Improving The Diagnosis Of Bipolar Disorder With Dried Blood Spot Metabolomics** biocrates The future of research and health Dried blood spot metabolomic profiling combined with digital assessment can help differentiate between bipolar disorder and major depression, enabling earlier, more objective and personalised diagnosis. JAKUB TOMASIK, Assistant Research Professor, **University of Cambridge**	**Solution Provider Presentation** vizgen Senior Representative, **Vizgen**	**Optimising Pharma R&D Through Digital Pathology, AI And CRO Integration** OracleBio This presentation explores practical strategies in quantitative digital pathology to support Pharma R&D, focusing on workflow efficiency, AI-driven data quality, and effective CRO engagement to drive faster, more reliable decision-making across the drug development pipeline. LORCAN SHERRY, Chief Scientific Officer, **OracleBio**
	Q&A session & transition time between conference rooms					
12:35	**Silver Level Solution Provider Presentation** *Attendees Are Welcome To Attend Co-Located Sessions*	**Solution Provider Presentation** *Attendees Are Welcome To Attend Co-Located Sessions*	**Capture The Landscape Of Disease Using Femtogram Level Sensitivity** MERCK Upgrades in immunoassay technology are advancing biomarker research. The new FemtoQuest™ system yields femtogram/mL sensitivity in many sample types, in both dual and single plex formats. This presentation will discuss high sensitivity detection of IL-17A and IL-17F in autoimmune disease. DANIEL GARCIA-WEST, Technology Manager, Proteins Pathways and Analysis, **Merck Life Science KGaA**	**Solution Provider Presentation** HURDLE Senior Representative, **Hurdle**	**From Sample To Report: Automated Spatial Biology Workflow With PhenoScout AI** ZEISS We present an end-to-end spatial biology workflow integrating ZEISS Axioscan 7 spatial biology, SlideStream, and Mindpeak's PhenoScout AI. Foundation AI models enable robust, reproducible analysis across diverse mIF/IHC stainings without any prior image analysis expertise, advancing scalable and robust spatial biology. CHRISTOPER MILLS, Senior Scientist, **Concept Life Sciences**	**How I Learned to Stop Worrying and Love IHC Biomarkers** PATHOMATION From Tamoxifen to AI, this talk shows how IHC biomarkers shape targeted therapies. We'll cover HER2, PD-L1, Claudin18, training's impact on adoption, lessons from failures, and how AI can extend pathologists' expertise in precision medicine. RUDY HOVELINCK, CEO, **Pathomation**
	Q&A session & transition time between conference rooms					

Day Two | October 01, 2025

	BIOMARKERS & PRECISION MEDICINE				SPATIAL BIOLOGY FOR PRECISION MEDICINE	DIGITAL PATHOLOGY & AI
	CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION & VALIDATION: NEUROSCIENCE & CO-MORBIDITY	CONF ROOM 2: **ST JAMES** - NEW & EMERGING BIOMARKER TECHNOLOGIES FOR ANALYSIS	CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL TRIALS	CONF ROOM 4: **ABBEY** - BIOMARKERS FOR DIAGNOSTICS & PRECISION MEDICINE	CONF ROOM 5: **GIELGUD & BURTON** - AI IMAGE ANALYSIS & DATA ANALYTICS IN SPATIAL BIOLOGY	CONF ROOM 6: **OLIVIER** - COMPUTATIONAL PATHOLOGY & UTILISING DIGITAL PATHOLOGY IN PHARMA RESEARCH
13:00	**Conference Room 1 - Panel Discussion - AI-Powered Precision Medicine:** **Moderator:** LAURENT AUDOLY, CEO, Co-Founder, **PriveBio Inc** **Panellists:** MANI MUDALIAR, Director of Quantitative Biomarkers, **Recursion** JIMMY BELL, Professor & Director, Research Centre for Optimal Health, **University of Westminster** DAVID SNEAD, Professor & Consultant Pathologist, **UHCW NHS Trust Coventry and Director of PathLAKE** BELINDA NEDJAI, Associate Professor, **Queen Mary University of London** ADAMA IBRAHIM, Vice President of Digital Transformation, Research and Early Development (R&D), **Novo Nordisk** INTERACTIVE				**Conference Room 5 - Panel Discussion - Exploring The Application Of Spatial Technologies In Immunology & Oncology** **Panellists:** MATTHEW HUMPHRIES, Director of Research Operations, **Leeds Teaching Hospitals NHS Trust** BERND WOLLSCHEID, Head of Institute for Translational Medicine, Professor & Group Head, **ETH Zurich** INTERACTIVE	**Conference Room 6 - Panel Discussion - Digital Pathology in Pharma – Overcoming Integration Strategies & Future Proofing** **Moderator:** ANA HIDALGO SASTRE, Director, Translational Science, **AstraZeneca** **Panellists:** JEAN-CHRISTOPHE OLIVO-MARIN, Professor & Head of the Quantitative Image Analysis Unit, **Institut Pasteur** MUHAMMAD ASLAM**,** Consultant Pathologist, National Clinical Lead for Digital Pathology & AI, Wales, **Betsi Cadwaladr University Health Board** Senior Representative, **Diagnexia Analytix** **(Reserved)** THIVYAN THAYAPARAN, Director, External Innovation & Partnerships, Precision Medicine, R&D, **GSK** INTERACTIVE
13:30	**LUNCH BREAK:** Poster Displays & 1-2-1 Meetings x4					
	Track Chair: Cristina Legido Quigley,Principal Investigator in Systems Medicine, **Kings College London**	*Track Chair:* James Schofield, Founder & Chief Executive Officer, **TopMD Precision Medicine**	*Track Chair:* Paul Rhyne, Senior Director, Scientific Solutions, **Luminex**	*Track Chair:* Valerie Taly, Group Leader, **University of Paris Descartes**	*Track Chair:* Azam Hamidinekoo, Associate Director, **AstraZeneca**	*Track Chair: TBA*
	Solution Provider Presentation ALAMAR BIOSCIENCES MAURA MALPETTI, Race Against Dementia ARUK Fellow Senior Research Associate, **UK DRI at Cambridge**	**Productising Your Biomarker** MEDTECH TO MARKET Providing an overview of the design, verification and validation stages for launching new biomarker technologies. Covering the regulatory requirements, key bench and clinical validation studies needed for a technical file submission. MATT PEARCE, Director, **Medtech To Market**	**Key Considerations For High Quality Data Generation In Global Clinical Trials** ICON The primary goal of clinical trials is to protect participant safety, with secondary goals including generating accurate, precise, and complete analytical datasets for global studies. High-quality databases enable efficient evaluation of a compound's safety and efficacy. This session highlights key factors influencing data quality in clinical trial execution. ANDREW ROCHE, Senior Director of Scientific Affairs, **ICON Laboratory Solutions**	**Realising The Full Potential Of Dx Concordance Studies: From Pragmatic Study Design To Accelerating Impactful Outcome** Diaceutics Better Testing, Better Treatment Traditional concordance studies lack real-world relevance. At Diaceutics, we rapidly mobilise scientific studies across independent labs in our network with pragmatic designs that reflect every day clinical practice. Our method delivers robust science along with meaningful operational insights to enhance launch strategies and overall brand impact. KEN RUPPEL, VP Scientific & Medical Services, **Diaceutics** DR CHRISTINE QUINN, Senior Director, **Diaceutics**	**From Tissue To Reliable Data: Ensuring Quality For Robust Image Analysis** HistologiX TOM ASHMORE , Business Development Manager, **Histologix**	**Unlocking Prognostic Biomarkers - Integrating Imaging And Omics With Foundation Models** SONRAI Pathology foundation models are redefining biomarker discovery. Learn how WSI embeddings and omics integration can unlock prognostic signals, with a practical pancreatic cancer case study built on public datasets. MATT LEE, Director of AI and Medical Imaging, **Sonrai Analytics**
14:50	*Q&A session & transition time between conference rooms*					

Day Two | October 01, 2025

BIOMARKERS & PRECISION MEDICINE

CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION & VALIDATION: NEUROSCIENCE & CO-MORBIDITY

15:15

Panel Discussion:
Biomarker Strategies In Neurodegenerative Therapeutics

- Enabling technologies and Imaging approaches to improve target engagement and early diagnostic biomarkers
- How best to incorporate biomarkers into drug development and clinical trials for neurodegenerative diseases
- Recent advancements in developing biomarkers for clinical utility

Moderator:
KIRI GRANGER, Chief Scientific Officer, **Monument Therapeutics**

Panellists:
MANUELA CERINA, Scientific Director of Neurodegeneration, **LifeArc**

NATASA GIALLOUROU, Field Metabolomics Scientist, **Metabolon**

KRISTINA HOLMBERG, Head of Clinical Biomarkers, **Lundbeck**

15:40

INTERACTIVE

CONF ROOM 2: **ST JAMES** - NEW & EMERGING BIOMARKER TECHNOLOGIES FOR ANALYSIS

Panel Discussion:
Application and Integration Of Proteomic Biomarkers In Precision Medicine

- Biomarker discovery,
- Diagnostics and prognostics,
- Patient stratification and precision medicine

Moderator:
KARL SMITH-BYRNE, Senior Molecular Epidemiologist, **Cancer Epidemiology Unit (CEU), University of Oxford**

Panellists:
OLGA NISSAN, CEO, **Protica Bio**

JOSHUA ATKINS, Senior Genomic Epidemiologist, **Cancer Epidemiology Unit (CEU), University of Oxford**

ALEXANDRA SEVKO, VP of Translational Science, **Amphista Therapeutics**

INTERACTIVE

CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL TRIALS

Panel Discussion:
Translating Biomarkers From Bench To Bedside

- Patient identification
- Endpoints

Moderator:
EMANUELA OLDONI, Scientific Lead of Personalised Medicine, **EATRIS, European Infrastructure for Translational Medicine**

Panellists:
MIKE MESSENGER, Head of Regulatory Strategy, **BIVDA**

MICHAEL CANNARILE, Head of Biomarkers, Early Development Oncology (EDO), Pharma Research & Development (pRED) **Roche Innovation Center Munich**

DAVID KRIGE, Head of Translational Sciences, **Accession Therapeutics**

LAURA HUBBARD, Operations Director, **Histologix**

INTERACTIVE

CONF ROOM 4: **ABBEY** - BIOMARKERS FOR DIAGNOSTICS & PRECISION MEDICINE

Panel Discussion:
Navigating Trends In Biomarker & Diagnostic Partnerships

Moderator:
SUSANNE MUNKSTEAD, CSO, **Diaceutics**

Panellists:
JENS KIECKBUSCH, Director of External Innovation, Precision Medicine, Research & Development, **GSK**

CHRIS BRAY, Head of Global Regulatory Affairs, Precision Medicine & Companion Diagnostics, **Merck KGaA**

NITIN JAIN, Director of Franchise Project Management, **AstraZeneca**

INTERACTIVE

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONF ROOM 5: **GIELGUD & BURTON** - AI IMAGE ANALYSIS & DATA ANALYTICS IN SPATIAL BIOLOGY

IO-FAST: Initiative For FAIR Spatial Data

IO-FAST (Initiative for FAIR Spatial Data) addresses the urgent need for standardised, interoperable spatial omics frameworks. By uniting academia, industry, and data repositories, we support the research community in harmonising data formats, streamlining metadata annotation, and fostering community collaboration-empowering researchers to share and integrate complex spatial datasets.

AMONIDA ZADISSA, Associate Director of Informatics, **UK Dementia Research Institute**

Q&A session & transition time between conference rooms

Data-Driven Analysis And Spatiotemporal Control Of Bacterial Colonies

The morphology of bacterial microcolonies influences key properties such as resource uptake and resistance to environmental stressors, including antibiotics. We present machine learning–based tools for analysing microscopy data and for spatiotemporal control of gene expression to precisely manipulate microcolony shape. These capabilities open new avenues for research and applications in biofilms, antibiotic resistance, diagnostics, and engineered biomaterials.

JEAN-BAPTISTE LUGAGNE, Assosiate Professor, **University of Oxford**

DIGITAL PATHOLOGY & AI

CONF ROOM 6: **OLIVIER** - COMPUTATIONAL PATHOLOGY & UTILISING DIGITAL PATHOLOGY IN PHARMA RESEARCH

Scaling Computational Pathology for the Next Generation Of Cancer Therapies: Challenges and Opportunities

This presentation explores the crucial role of the pharmaceutical industry in expanding digital pathology accessibility across global immunohistochemistry laboratories. By leveraging computational approaches, we can revolutionise biomarker detection in cancer patients. The session will highlight innovative strategies and collaborative efforts needed to overcome current challenges and drive advancements in personalised medicine, ultimately enhancing patient outcomes on a global scale.

HUW BANNISTER, Senior Director of Global Diagnostics, Digital and Computational Pathology, **AstraZeneca**

Revolutionising Image Analysis In Drug Discovery

At AstraZeneca, we are embedding AI, image analysis and frameworks for integrating emerging multi-omic data into our digital toxicological pathology workflows. This is providing novel insights and a dynamic, integrated understanding of tissues, disease, and the impact of our therapies upon drug therapeutic indices. This enables a seamless and scalable digital revolution to support our accelerated drug discovery portfolio.

ARTHUR LEWIS, Director of Image Analysis & Platform, Pathology, **AstraZeneca**

Day Two | October 01, 2025

	BIOMARKERS & PRECISION MEDICINE				SPATIAL BIOLOGY FOR PRECISION MEDICINE	DIGITAL PATHOLOGY & AI
	CONF ROOM 1: **WESTMINSTER** - BIOMARKER IDENTIFICATION & VALIDATION: NEUROSCIENCE & CO-MORBIDITY	CONF ROOM 2: **ST JAMES** - NEW & EMERGING BIOMARKER TECHNOLOGIES FOR ANALYSIS	CONF ROOM 3: **MOORE** - BIOMARKERS FOR CLINICAL TRIALS	CONF ROOM 4: **ABBEY** - BIOMARKERS FOR DIAGNOSTICS & PRECISION MEDICINE	CONF ROOM 5: **GIELGUD & BURTON** - AI IMAGE ANALYSIS & DATA ANALYTICS IN SPATIAL BIOLOGY	CONF ROOM 6: **OLIVIER** - COMPUTATIONAL PATHOLOGY & UTILISING DIGITAL PATHOLOGY IN PHARMA RESEARCH
16:05	**Antibodies From Resilient Individuals: A Novel Approach For Neurodegeneration Drug Discovery** Alchemab use a patient first, target agnostic approach to drug discovery that often results in novel targets with unexplored biology and with no high quality commercial reagents available to study them. This talk will provide examples of overcoming these challenges by developing novel assays and tools. HELEN GRAVES, Principal Scientist, **Alchemab Therapeutics**	**Biomarkers For Treatment Response In Prostate Cancer** • Mechanism-centric biomarker discovery • Patient risk of treatment failure assessment • Novel therapeutic vulnerabilities • MYC+NME2 as markers and therapeutic targets for advanced prostate cancer ANTONINA MITROFANOVA, Associate Dean for Research & Associate Professor, **Rutgers University**	**Accelerating Clinical Trials In Neurodegenerative Disease Using Wearable Sensors And AI-Derived Kinematic Biomarkers** Our work demonstrates how data-derived wearable biomarkers can track personal disease trajectories and indicates the potential of such biomarkers for substantially reducing the duration or size of clinical trials testing disease-modifying therapies and for enabling behavioural transcriptomics. RICHARD FESTENSTEIN, Clinical Professor of Molecular Medicine, Department of Brain Sciences, **Imperial College London**	**Epigenetic Detection Of HPV-Related Cancers: Validation Of The S5 Classifier In African And Global Low-Resource Settings** The S5 methylation classifier is a liquid biopsy-based tool that detects early cancer-related epigenetic changes across multiple HPV-associated malignancies. Applicable to self-collected or clinician-obtained samples, it has demonstrated high accuracy in diverse global populations. Its non-invasive, scalable design supports early detection in low-resource settings, highlighting its potential for broad integration into biomarker-driven cancer screening programmes. BELINDA NEDJAI, Associate Professor, **Queen Mary University of London**	**Spatially Resolved Multiomics Of Human Cardiac Niches** We combine single-cell and spatial transcriptomics to discover human cardiac niches. We profile cardiac conduction system cells, revealing that the pacemaker cells exhibit distinct characteristics in the adult and developing heart. In the ventricle, we illustrate the processes of cardiomyocyte compaction and maturation. Overall, we offer a comprehensive map of the human heart, both in adults and during development. KAZUMASA KANEMARU, Postdoctoral Researcher, **Cambridge Stem Cell Institute, University of Cambridge**	**AI Quantification In H&E Stained Tissue** FRANCESCA TRAPANI, Scientific Director & Molecular Pathology Laboratory Head, **Boehringer Ingelheim**
	Q&A session & transition time between conference rooms					
16:30	**Mapping Neurodegeneration: Multi-Omics Insights Into Disease and Preclinical Models** Use multi-omics platforms to better understand neurodegenerative diseases and assess how well preclinical models reflect human disease. Combined targeted and untargeted omics to analyse plasma, CSF, and brain tissue, revealing differentially expressed molecules. Multi-omics shows promise for biomarker discovery, and clinical relevance. GAYLE MARSHALL, Head of Biomarkers, **Medicines Discovery Catapult**	**A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib** By analysing gene expression in cancer cell lines that are sensitive and resistant to the dual PARP and Tankyrase inhibitor Stenoparib, Allarity has developed a response predictor. Validation in a clinical trial is ongoing. THOMAS JENSEN, Chief Executive Officer, **Allarity**	**Epigenetic Biomarkers For Inflammatory Disease** WOUTER DE JONGE, Professor of Neurogastroenterology, **Amsterdam UMC**	**Biomarkers For Early Detection Of Cancer And/ Or Enabling Development & Delivery Of Cancer Preventative Interventions** Novel interventions to reduce risk and intercept cancer at its earliest stages could benefit both patients and health systems. To make precision prevention a reality, there is a critical need to develop cancer risk biomarkers and surrogate endpoints. This talk provides an overview of CRUK's cancer prevention strategy, and our perspectives on the challenges and opportunities for cancer prevention biomarkers. JOANNA JANUS Research Programme Manager, (Early Detection & Prevention), **Cancer Research UK**	*Attendees Are Welcome To Attend Co-Located Sessions*	**How AI Is Shaping Prostate Cancer Diagnosis** • IPATIMUP experience with AI. • Clinical advantages of AI-guided prostate biopsies. • Transformative potential of AI in shaping the future of prostate cancer diagnosis. JOÃO PINTO, Medical Specialist, Institute Molecular Pathology and Immunology, **University of Porto (Ipatimup)**
16:55	**END OF CONFERENCE**					

VENUE INFORMATION

Experience London

Biomarkers & Precision Medicine 2025 will be held at the Queen Elizabeth II Centre.

Since 1986, The QEII Centre has been London's premier venue for domestic and international events. Their venue offers world-class facilities for high-profile conferences, conventions, exhibitions and corporate events with a capacity of up to 2,500.

Located opposite Westminster Abbey, the QEII Centre is less than a five minute walk from the Thames, and a two-minute walk from a royal park. The Centre is served by exceptional transport links providing easy access to everything the city has to offer, from world-class restaurants and nightlife to shopping and culture. Within an hour's transfer from five international airports, you will have an effortless journey to the Centre.

DRIVING

Blue badge holders are permitted to park on the QEII Centre forecourt free of charge. Parking in this location is subject to availability so please call ahead on +44 20 7798 4000 to enquire.

Disabled passengers arriving by taxis or alternative vehicles may disembark on the forecourt.

PUBLIC TRANSPORT

The nearest step-free tube station is Westminster, which is served by the Jubilee, District and Circle lines.

Venue Website